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All opioids - whether they are addictive opioid analgesics or endogenous opioids 
like endorphins produced by our body - activate one of three receptors in our brain. 
However, different opioids cause different effects, including effects on pain and addiction. How 
opioids generate this variety in signaling has been a long-standing question in the field. My 
thesis tests the exciting new idea that specific opioids traffic receptors to different compartments 
of the cell, from where they can signal in a compartment-specific manner.  
In this dissertation I review the selective mechanisms that regulate G protein-coupled 
receptor (GPCR) trafficking, which highlight the complex framework underlying spatial 
regulation of receptor function. Lipid membrane dynamics, post-translational modifications, cell-
specific protein interactors, and agonist-selectivity are all key determinants for selective GPCR 
trafficking.  
Specifically, I focus on how opioid peptides may cause distinct functional outcomes 
through activation of the same receptor. To address this question, I use high-resolution imaging 
assays to examine how different dynorphin peptides regulated kappa opioid receptor (KOR) 
trafficking and post-endocytic sorting. Interestingly, we observe that highly related dynorphin 
peptides caused distinct opioid receptor trafficking fates (recycling vs. degradation) as well as 
compartment-specific signaling from late endosomes and lysosomes, depending on the peptide 
ligand that activated the receptor. Specifically, we show that KOR activation by dynorphin A 
leads to receptor degradation and activation from late endosomal compartments, while KOR 
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activation by the highly related dynorphin B leads to receptor recycling from Rab5 and Rab11 
compartments, without endosomal signaling. 
 Further, I investigate the dynamic relationship between receptor signaling and receptor 
trafficking. Initially, we observed that agonist washout caused a decrease in mu opioid receptor 
(MOR) recycling. This finding led us to hypothesize that signaling downstream of receptor 
activation regulated receptor trafficking back to the cell surface, which regulates resensitization. 
To test this, I used total internal reflection fluorescence (TIRF) microscopy to detect real-time 
exocytic fusion events in living cells. I tested various components of known signaling pathways 
downstream of MOR activation using pharmacological inhibitors and phosphodeficient and 
phosphomimetic receptor mutants to quantitate differences in MOR recycling. Our results 
indicate that MOR recycling is regulated via an agonist-dependent Gβγ signaling pathway, 
resulting in the phosphorylation of the receptor’s C-terminal tail to increase receptor recycling. I 
follow up on this work by further testing the role of receptor phosphorylation in regulating MOR 
trafficking and signaling. By understanding the signaling pathways that regulate receptor 
trafficking and resensitization, this work opens new avenues for potential druggable targets. 
Collectively, this work increases our understanding of opioid physiology. Further, 
because the opioid receptor is a prototype for GPCRs - the largest and highly conserved family 
of signaling receptors in humans - the principles could be relevant across many physiologically 
relevant members of this family. 
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Chapter 1 Introduction 
 
 
1.1 Mechanisms of Selective G protein-coupled Receptor 
Localization and Trafficking 
 
Published as Kunselman, J. M., Lott, J., & Puthenveedu, M. A. (2021). Mechanism of Selective 
GPCR Trafficking. Curr. Opin. Cell Biol. 71, 158-165. 
Abstract 
The trafficking of G protein–coupled receptors (GPCRs) to different membrane 
compartments has recently emerged as being a critical determinant of the signaling profiles of 
activation. GPCRs, which share many structural and functional similarities, also share many 
mechanisms that traffic them between compartments. This sharing raises the question of how the 
trafficking of individual GPCRs is selectively regulated. Here, we will discuss recent studies 
addressing the mechanisms that contribute to selectivity in endocytic and biosynthetic trafficking 
of GPCRs. 
Introduction 
The regulation of signaling by membrane trafficking has traditionally been attributed to 
trafficking’s role in controlling the number of signaling receptors on the cell surface (Sorkin and 
von Zastrow, 2009). For G protein-coupled receptors (GPCRs), the largest single family of 
signaling receptors (Pierce et al., 2002), the removal of activated receptors from the cell surface
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by endocytosis and recovery of receptors on the surface by either recycling of internalized 
receptors or delivery of new receptors control the strength of response to extracellular ligands 
(Hanyaloglu and von Zastrow, 2008; Hausdorff et al., 1990). Recent studies, however, have 
highlighted more complex aspects of how trafficking regulates signaling. One is that GPCRs can 
signal from a variety of intracellular compartments (Sposini and Hanyaloglu, 2018; Lobingier 
and von Zastrow, 2019). Another is that mechanisms that regulate GPCR trafficking are 
heterogeneous, allowing selective control over the location and trafficking of individual GPCRs 
(Hanyaloglu and von Zastrow, 2008). These aspects have highlighted a new idea that the primary 
role of trafficking might be to move specific GPCRs between specific signaling complexes on 
different membrane domains, as opposed to simply regulating cell surface receptors (Crilly and 
Puthenveedu, 2020; Calebiro and Koszegi, 2019). In this review, we will discuss recent studies 
on endocytic and biosynthetic trafficking of GPCRs, focusing on example mechanisms that 
provide specificity in the midst of shared mechanisms.  
Endocytic trafficking  
The mechanisms of GPCR endocytosis and post-endocytic trafficking after receptor 
activation, which are common features of many GPCRs, have been exhaustively addressed in 
several reviews (Hanyaloglu and von Zastrow, 2008; Bowman and Puthenveedu, 2015; Bahouth 
and Nooh, 2017; Weinberg and Puthenveedu, 2019). We will discuss recent findings on receptor 





Selectivity in endocytosis of GPCRs  
How the endocytosis of GPCRs is individually controlled has been a long-standing 
question, considering that the general mechanism is shared broadly across most GPCRs 
(Weinberg and Puthenveedu, 2019). Activated GPCRs undergo specific conformational changes 
that, in addition to catalyzing guanosine triphosphate (GTP) exchange on G proteins, allow 
GPCR kinases to phosphorylate the receptor C-termini. These phosphorylated C-termini are 
recognized by arrestins, which act as adapters that link receptors to the clathrin endocytic 
machinery (Tian et al., 2014; Gurevich and Gurevich, 2019A; Caron and Barak, 2019).   
One aspect of this process that could be selective is receptor phosphorylation. Many 
GPCRs have multiple phosphorylation sites on its C-terminal tail, which are required for receptor 
internalization (Patwardhan et al., 2021; Gurevich and Gurevich, 2019B). For example, in the 
mu-opioid receptor (MOR), a phosphorylation cluster within residues 375-379 is the primary 
mediator of endocytosis (Lau et al., 2011; Arttamangkul et al., 2019), which might be driven 
mainly by GRK2 in HEK293 cells (Bouley et al., 2020). C-terminal sites may be phosphorylated 
hierarchically by multiple kinases (Just et al., 2013; Duarte and Devi, 2020), suggesting that each 
GPCR could have a set of kinases that phosphorylate it and drives endocytosis. For example, the 
receptor tyrosine kinase anaplastic lymphoma kinase (ALK) associates with the dopamine D2 
receptor (D2R) but not the closely related dopamine D1 receptor. An inhibitor of ALK blocks 
internalization of D2R but not of D1R. ALK-mediated activation of protein kinase C g (PKCg) 
downstream of dopamine is required and sufficient for D2R internalization in HEK293 cells (He 
and Lasek, 2020). The exact ALK-dependent internalization mechanism is not clear, but PKCg 
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may influence the phosphorylation patterns of D2R and target interactions between D2R and 
arrestin.  
For the vasopressin 2 receptor (V2R), differences in phosphorylation at specific residues 
tuned the strength of arrestin interactions and regulate endocytosis. Mutation of Ser 357 or Thr 
360 to alanines reduced arrestin binding as measured by co-immunoprecipitation but still 
retained enough binding to be visualized as membrane recruitment by microscopy. This reduced 
binding in the case of Ser 357 mutation was still sufficient for qualitatively similar levels of V2R 
and arrestin localization to endosomes. In contrast, reduced binding in the case of Thr 360 
mutation abolished arrestin localization to endosomes, although its effect on V2R endocytosis 
was not directly measured (Dwivedi-Agnihotri et al., 2020). Similarly, a naturally occurring 
variant at Thr 282 for the angiotensin II receptor 1 induced a distinct conformation of arrestin 
upon binding, which was less stable but still supported endocytosis (Cao et al., 2020). The 
second aspect of endocytosis that could be selective are “checkpoints” that exist after GPCR 
localization to endocytic domains (Figure 1.1). GPCR C-terminal tails contain specific sequences 
that interact with several components of the endocytic machinery. For example, a type I PDZ 
ligand on the C-terminus of the beta 2 adrenergic receptor indirectly links receptors to the actin 
cytoskeleton in clathrin-coated pits. This link delays the recruitment of dynamin, a GTPase that 
is required for membrane scission during endocytosis (Puthenveedu and von Zastrow, 2006). In 
contrast, PDZ-mediated interaction of mGluR1 and mGluR5, two metabotropic glutamate 
receptors, with the scaffold protein tamalin is essential for receptor endocytosis (Pandey et al., 
2020). In this case, tamalin might link the receptors to motors via a scaffold protein S-SCAM, 
suggesting that it acts at a late step. An unrelated “bileucine” sequence on the C-terminal tail of 
MOR delays scission even after dynamin is recruited (Weinberg et al., 2017). The same receptor 
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might contain multiple discrete sequences that regulate endocytosis. The first intracellular loop 
of MOR contains specific lysines that are ubiquitinated by the ubiquitin ligase Smurf2. This 
ubiquitination, recognized by the endocytic accessory protein Epsin1, is required for endocytic 
scission (Henry et al., 2012). For the protease-activated receptor 1, ubiquitination- dependent 
recruitment of Epsin1 and the endocytic adapter AP-2 can induce receptor endocytosis in the 
absence of arrestins (Chen et al., 2011). The third intracellular loop of the beta 1 adrenergic 
receptor (B1AR) recruits endophilin, a BAR domain-containing protein that generates membrane 
curvature as part of the endocytic machinery, when linked to Giant Unilamellar Vesicles. 
Endophilin, once recruited via interactions of the third loop with the endophilin SH3 domain, can 
generate membrane curvature on these vesicles (Mondal et al., 2021). Specific local protein 
interactions of individual GPCRs might therefore delay or facilitate their own endocytosis by 




Figure 1.1 GPCR endocytosis is regulated by selective mechanisms. GPCR endocytosis from 
the plasma membrane can be regulated at multiple steps. The 5-HT1AR can switch between 
clathrin-dependent or caveolin-dependent endocytosis depending on cholesterol levels in the 
plasma membrane, which suggests that GPCR endocytosis can be regulated by the local 
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membrane environment. GPCR interactions with arrestin, a shared endocytic adapter, could be 
regulated by the slate of kinases that determine the phosphorylation patterns on the GPCR C-
termini. The GPCR C-termini and cytoplasmic loops contain additional sequences that regulate 
later steps in endocytosis by interacting with structural scaffold proteins such as PDZ proteins or 
tamalin. Although these mechanisms are still not fully understood, newer methods including high 
resolution live cell microscopy and single molecule tracking may help us decipher the interplay 
between these factors, GPCRs, and the endocytic machinery. 
A third aspect is the selective interaction of GPCRs with membrane lipids. The third 
intracellular loop of the B1AR, described previously, electrostatically interacts with anionic 
phospholipids, which interfere with SH3 recruitment (Mondal et al., 2021). GPCRs might 
localize to micro- domains, such as lipid rafts or caveolae on the surface, often in a regulated 
manner (Patel et al., 2008; Briddon et al., 2018). Activation of the glucagon-like peptide-1 
receptor (GLP-1R) in pancreatic beta cells redistributes the receptors to membrane nanodomains 
that contain the lipid raft marker flotillin (Buenaventura et al., 2019). When cholesterol was 
depleted by methyl-b-cyclodextrin, GLP-1R failed to redistribute to nano- domains and to 
internalize. Receptor palmitoylation and different agonists regulated this redistribution, raising 
the possibility that the process could be regulated by signaling. The role that cholesterol 
interactions play could be specific for each GPCR. When cholesterol was depleted by statin 
drugs, 5-HT1A receptors (5-HT1AR) internalized, but the pathway switched from clathrin- 
mediated to caveolin-mediated endocytosis (Kumar and Chattopadhyay, 2020). Interestingly, 
when cholesterol was depleted to similar levels using methyl-b-cyclodextrin, 5-HT1AR still 
internalized via a clathrin-mediated pathway, although post-endocytic sorting was altered 
(Kumar and Chattopadhyay, 2021).  
Several cholesterol-binding motifs, termed cholesterol consensus motifs, cholesterol 
recognition amino acid consensus (CRAC) motifs, or CARC motifs when they exist in reverse, 
have been identified in GPCRs (Fantini et al., 2016; Fatakia et al., 2019). In many cases, the 
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motifs have been functionally confirmed as being required for normal GPCR trafficking. A 
recent analysis of structural data across available GPCR structures, however, concluded that 
CRAC motifs are not predictive of cholesterol binding (Taghon et al., 2021). One potential way 
to reconcile these observations is that the motifs reflect potential hot spots of interactions (Sarkar 
and Chattopadhyay, 2020). Another way is to consider that lipid binding might be hierarchical, 
where allosteric changes caused by lipid binding on one site increases or decreases the affinity of 
other lipid-binding sites. In this context, it is important to note that the structural informatics 
(Taghon et al., 2021) was based largely on structures generated under conditions using 
synthesized lipids or detergents, which are different from in vivo environments where a full 
complement of lipids and proteins are present. Overall, much less is known about how lipids 
interact with GPCRs, compared with how proteins interact with GPCRs.		
Selectivity in post-endocytic trafficking of GPCRs  
Internalized GPCRs typically have two fates once they are internalized and trafficked to 
the endosomal system. They may recycle back to the cell surface or may be degraded in the 
lysosome (Bowman and Puthenveedu, 2015; Bahouth and Nooh, 2017). Nutrient receptors such 
as the transferrin receptor are recycled largely by bulk membrane flow (Mayor et al., 1993), but 
GPCR recycling requires specific sequences on receptors. These sequences both restrict GPCRs 
from recycling by bulk flow and direct GPCRs to sequence-dependent recycling or degradation 
(Hanyaloglu and von Zastrow, 2008; Bahouth and Nooh, 2017). Mutating two protein kinase A 
(PKA) phosphorylation sites on B2AR converts the receptor into a bulk recycling protein, 
suggesting that bulk sorting is hierarchically above sorting between sequence-dependent 
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recycling and degradation (Vistein and Puthenveedu, 2013). At present, the factors that restrict 
GPCRs from accessing the bulk recycling pathway are not known.  
Spatial segregation of GPCRs in the endocytic pathway. 
The endolysosomal system is now recognized as a complex mix of partially overlapping 
membrane systems that constantly mature along the endocytic pathway (Figure 1.2). The current 
model is that endocytosed GPCRs pass through the very early endosome (VEE) to the early 
endosome (EE). The VEE is marked by APPL1 but devoid of Rab5 and EEA1, which mark the 
EE. The luteinizing hormone receptor (LHR) and the follicle- stimulating hormone receptor 
(FSHR) are localized to the VEE after activation (Jean-Alphonse, et al., 2014). Many other 
GPCRs such as the prototypical B2AR are localized mainly to EE after activation (Puthenveedu 






Figure 1.2. A sequential model for GPCR sorting throughout the endolysosomal network. 
After internalization from the plasma membrane, GPCRs are sequentially transported through the 
VEE and EE, at which point they are sorted into the RE or the late endocytic/degradative 
pathway. These compartments are marked by specific biochemical components. GPCRs can 
interact with specific recycling trafficking proteins in these compartments that direct them to the 
recycling pathway. Selected examples of markers for compartments and GPCRs that recycle 
from them are shown. It is important to note that these compartments are depicted separately to 
denote where the majority of components are at steady state. In vivo, these compartments are 
likely to overlap significantly because of dynamic membrane exchange and maturation. 
The steady-state segregation of GPCRs in distinct compartments likely represents receptor 
recycling from that compartment. LHR and FSHR are rapidly recycled from the VEE via 
interactions of receptor C-termini with the PDZ-containing protein GIPC. Disrupting PDZ-GIPC 
interactions decreases recycling and shifts the steady state distribution of LHR to the EE and 
later compartments (Jean-Alphonse, et al., 2014). Similarly, B2AR is recycled from the EE by 
interactions of a PDZ ligand on its C-terminal tail with proteins in the actin-sorting nexin-
retromer tubular domains of endosomes. Disrupting PDZ interactions decreases recycling and 
drives B2AR into the late endosomal pathway to be degraded (Cao et al., 1999). For the atypical 
chemokine receptor 3, overexpression of RAMP3, a PDZ-containing member of a family of 
single-transmembrane proteins that associate with GPCRs, and NSF qualitatively changes 
receptor localization from Rab7 late endosomes to Rab4 early endosomes, after an hour of 
agonist treatment and 4 h of washout (Mackie et al., 2019). GPCRs in the EE may also be 
trafficked to a dedicated recycling endosome marked by Rab11, from which they can recycle. 
Receptor interactions with these specific components and localization depend on a slate of 
posttranslational modifications on the receptor, such as phosphorylation or ubiquitination 




Regulation of GPCR sorting by signaling  
Signaling pathways downstream of the same receptor (homologous) or other receptors 
(heterologous) could selectively regulate the rates of sorting and recycling of GPCRs by 
inducing posttranslational modifications on select GPCRs. B2AR activity reduces the rate of 
B2AR recycling via receptor phosphorylation by PKA (Vistein and Puthenveedu, 2013). MOR 
activity, however, increases MOR recycling independent of PKA via phosphorylation at Ser 363 
and Thr 370 by PKC downstream of receptor activation (Kunselman et al., 2019). The same sites 
on MOR can also be phosphorylated by PKC downstream of neurokinin-1 signaling to increase 
MOR recycling and resensitization, allowing for cross- talk between these signaling pathways 
(Bowman et al., 2015). For the chemokine receptor CXCR4, however, PKC activation drives 
receptor degradation, suggesting that the same signaling pathway can affect different receptors 
differently (Caballero et al., 2019). PKC phosphorylation of CXCR4 at Ser 324/ 325 recruits the 
ubiquitin ligase AIP4. PKC was sufficient but not necessary for CXCR4 degradation, suggesting 
that another kinase might phosphorylate one of these residues and recruit AIP4 (Caballero et al., 
2019). Importantly, post-endocytic sorting mechanisms might be leveraged by physiological 
systems to fine tune the effects of receptor activation. Two endogenous ligands regulated the 
post-endocytic fate of the kappa opioid receptor (KOR) differently (Kunselman et al., 2021). 
Dynorphin B caused KOR to rapidly recycle via Rab11, whereas Dynorphin A caused KOR to 
be degraded in the lysosomes. Interestingly, KOR localized to the lysosomes was able to signal 





Biosynthetic trafficking  
The folding and export of GPCRs from the endoplasmic reticulum is regulated by a 
variety of interacting proteins and by exogenous drugs that act as chaperones (Zhang and Wu, 
2019; Doly and Marullo, 2015). In contrast, whether and how GPCR trafficking after ER export 
is regulated is less well understood. In this section, we will discuss recent data describing the 
heterogeneous mechanisms that regulate GPCRs transport from compartments after ER export 




Figure 1.3. Post-Golgi trafficking of GPCRs can be regulated by diverse mechanisms. 
Example pathways by which GPCR export can be regulated. GPCRs such as the ⍺-2B adrenergic 
receptor and angiotensin II receptor type I are exported by interactions with GGA proteins. 
SSTR5 and B1AR are retained in the Golgi via interactions with PIST, a PDZ-binding 
protein. DOR, on the other hand, is kept in the Golgi by constant retrieval via COPI interactions. 
CB1 is routinely trafficked to lysosomal compartments via AP-3 interactions, and disrupting 
these interactions redirects receptors to the plasma membrane. It is possible that additional 
pathways exist and that these pathways and interactions are relevant to different receptors in 




Many “general” trafficking proteins, such as small monomeric GTPases and their 
interactors, have been implicated in GPCR export from the Golgi apparatus (Zhang and Wu, 
2019). For example, the trafficking of a2B-adrenergic receptors depends on the Golgi-localizing, 
gamma-adaptin ear homology domain, ARF-binding (GGA) family of proteins and Rab26 
(Zhang et al., 2016A; Zhang et al., 2016B; Wei et al., 2019). GGA1, 2, and 3 all interact with the 
third intracellular loop of a2B-adrenergic receptor, although by different mechanisms. Depleting 
any one of the GGAs causes a partial reduction in surface delivery of a2B-adrenergic receptor, 
suggesting that each of them is partially required. GGA3 binds an RRR motif in the loop, 
whereas GGA1 and 2 do not. GGA3 depletion reduces export also of a2C-adrenergic receptors, 
but not of a2A-adrenergic receptors. Rab26 also binds the same intracellular loop in a GTP-
dependent manner, regulated by the putative GAP TBC1D6 (Wei et al., 2019). Unlike for 
GGA3, linear motifs on the receptor required for GGA1, GGA2, or Rab26 could not be 
identified by deletion studies, suggesting that they may bind a multipartite motif based on a 
specific conformation of the loop. Interestingly, an alternatively spliced variant of GGA1 lacks 
the hinge region of GGA1 that interacts with the a2B-adrenergic receptor, suggesting that 
isoform expression could provide selectivity (Zhang et al., 2019). As another example, the export 
of PAR2 from the Golgi requires the activation of protein kinase D (PKD). In this case, PKD is 
activated by Gβγ translocation to the Golgi after PAR activation, causing a feedback loop for 
repopulating the surface after receptor downregulation (Zhao et al., 2019). Gβγ and PKD are 
required for general TGN export (Diaz Anel and Malhorta, 2005), and whether other cargo 
molecules are also regulated downstream of PAR2 activation is not clear. Nevertheless, it is clear 
that some GPCRs use the predominant TGN export pathways to traffic to the cell surface.  
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Selective mechanisms that localize specific GPCRs without affecting trafficking in 
general have also been recently identified. The Leukotriene B4 Receptor Type 2 (BLT2) contains 
an unidentified sequence on its C- terminal tail, which enables it to interact with the scaffold 
protein LIN7C (Hara et al., 2021). A truncated BLT2 without this tail accumulates in the Golgi. 
But when LIN7C is depleted, BLT2 accumulates in intracellular compartments not restricted to 
the Golgi. In contrast, over- expression of the PDZ protein PIST localizes somatostatin receptor 
5 and B1AR to the Golgi (Wente et al., 2005; Koliwer et al., 2015), presumably by interacting 
with the C-terminal PDZ ligand on the receptor.  
The delta opioid receptor (DOR) provides a unique and interesting example of a GPCR 
whose Golgi localization is cell type specific and highly regulated. In neurons, newly 
synthesized DOR is retained in intracellular compartments that overlap with the Golgi, but in 
nonneuronal cells, DOR is efficiently expressed on the surface (Shiwarski et al., 2017A; 
Gendron et al., 2016). This Golgi localization is highly regulated by signaling. In the 
neuroendocrine PC12 cells, DOR is normally expressed at the cell surface, but a short exposure 
to Nerve Growth Factor, which inhibits phosphoinositide 3 kinase class 2 and reduces PI(3,4)P 
levels, induces Golgi localization of DOR (Shiwarski et al., 2017B). The current model for this 
retention is that in neurons or in NGF-treated PC12 cells, DOR is constantly retrieved to earlier 
compartments in the Golgi by regulated interactions with the coatomer protein 1 (COPI) 
complex. DOR contains two atypical COPI-binding RXR motifs in its C-terminal tail (Shiwarski 
et al., 2019), which are required and sufficient for regulated Golgi localization. DOR contains 
additional canonical COPI-binding motifs in the second and third intracellular loops (St. Louis et 
al., 2017), which could contribute to a basal level of intracellular DOR. At present, whether these 
interactions are regulated is not known.  
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In contrast to DOR, endogenous cannabinoid receptor 1 (CB1R) is localized to the late 
endosomal compartments and axonal surface in hippocampal neurons (Rozenfeld and Devi, 
2008; Fletcher-Jones et al., 2019). The late endosomal localization could be because of the 
shunting of CB1R in the TGN to an adaptor protein 3demediated export pathway (Rozenfeld and 
Devi, 2008). The deletion of helix 9 (H9) in the C-terminus caused CB1R to lose axonal 
polarization, but it was still delivered to the surface (Fletcher-Jones et al., 2019). This suggests 
that the receptor might be able to access multiple export pathways out of the TGN. The 
mechanism by which H9 regulates export is not known. The amphipathic nature of the helix 
might play a role, as amphipathicity of H8 was required for the export of apelin receptor from 
intracellular compartments and for efficient surface expression (Pandey et al., 2019).  
Outside of specific adapters and interacting proteins, receptor oligomerization is an 
exciting possibility that could provide specificity to trafficking. For example, the transport 
protein RTP4 interacts with MOR and DOR and selectively increases expression of heteromers 
on the surface (Decaillot et al., 2008), without affecting individually expressed MOR and DOR 
or CB1R or dopamine 2 receptors (Fujita et al., 2019). Overall, the diversity of mechanisms that 
regulate Golgi retention and export suggest that GPCR delivery via the secretory pathway could 
be selectively regulated for individual GPCRs.  
Conclusions  
The subcellular location of GPCRs could be a master regulator of GPCR function, as the 
list of GPCRs capable of signaling from intracellular compartments is rapidly growing (Sposini 
and Hanyaloglu, 2018; Lobingier and von Zastrow, 2019; Crilly and Puthenveedu, 2020). 
Modulating signals from specific compartments, by either relocating receptors to the plasma 
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membrane (Bowman et al., 2015; Shiwarski et al., 2017A) or specifically targeting signaling 
from endosomes (Jimenez-Vargas et al., 2020), has clear effects on signaling and behavior. As 
we develop sophisticated tools to study both the mechanisms of selective trafficking and 
localized signaling of GPCRs (Calebiro and Grimes, 2020; Halls and Canals, 2018; Maziarz et 
al., 2020), we will be able to generate a more precise understanding of spatial patterns of 
signaling for each member of this important family of signaling receptors.  
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Chapter 2: Compartment-specific Opioid Receptor Signaling is 
Selectively Modulated by Different Dynorphin Peptides 
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Compartment-specific opioid receptor signaling is selectively modulated by different Dynorphin 




Many signal transduction systems have an apparent redundancy built into them, where 
multiple physiological agonists activate the same receptors. Whether this is true redundancy, or 
whether this provides an as-yet unrecognized specificity in downstream signaling, is not well 
understood. We address this question using the kappa opioid receptor (KOR), a physiologically 
relevant G protein-coupled receptor (GPCR) that is activated by multiple members of the 
Dynorphin family of opioid peptides. We show that two related peptides, Dynorphin A and 
Dynorphin B, bind and activate KOR to similar extents in mammalian neuroendocrine cells and 
rat striatal neurons, but localize KOR to distinct intracellular compartments and drive different 
post-endocytic fates of the receptor. Strikingly, localization of KOR to the degradative pathway 
by Dynorphin A induces sustained KOR signaling from these compartments. Our results suggest 
that seemingly redundant endogenous peptides can fine-tune signaling by regulating the 





The endogenous opioid system provides an excellent and physiologically relevant example 
to study redundancy in signaling systems in our body. Over 20 endogenous opioids have been 
identified, all of which preferentially activate one of three opioid receptors – delta, kappa, and 
mu opioid receptors – which are all members of the G protein-coupled receptor (GPCR) family 
of proteins (Gendron et al., 2016; Chavkin, 2013; Williams et al., 2013). All these opioid 
peptides activate their cognate GPCRs broadly at similar levels in most of the readouts that have 
been used to measure activation (Sternini et al., 2013). Whether all these opioid peptides are 
truly redundant or whether they contribute to signaling diversity beyond the initial signaling has 
been a long-standing question in the field.  
Signaling from intracellular compartments, after the initial signaling from the surface, is 
emerging as a key determinant of the downstream consequences of receptor activation (Irannejad 
et al., 2013; Yarwood et al., 2017; Eichel and von Zastrow, 2018). While this is still an emerging 
field, a growing body of evidence suggests that GPCRs are active in endosomes and other 
intracellular compartments, and that receptors in endosomes can cause distinct signaling 
outcomes compared to receptors on the cell surface (Vilardaga et al., 2014; Bowman et al., 2016; 
Stoeber et al., 2018). Receptors rapidly and dynamically move between intracellular 
compartments and the surface by trafficking. Trafficking could therefore act as a master 
regulator of GPCR signaling by selectively amplifying signals from specific locations (Weinberg 
et al., 2019; Hanyaloglu, 2018). Whether physiological systems take advantage of trafficking to 
localize receptors to different compartments and dictate location-biased signaling, however, is 
still unanswered.  
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Here we bridge both questions by asking whether different endogenous opioid peptides can 
sort receptors to distinct intracellular compartments and drive different location-biased signaling 
outcomes. Using the kappa opioid receptor (KOR) as a model GPCR, we show that although 
related Dynorphin peptides can activate KOR on the surface to a similar extent, they induce 
different trafficking fates and endosomal localization of the receptor. Dyn B predominantly 
localized KOR to Rab11 recycling endosomes and caused KOR recycling, while Dyn A 
predominantly localized KOR to late endosomes and caused KOR degradation. Strikingly, Dyn 
A-activated KOR, but not Dyn B-activated KOR, was in an active conformation in lysosomes 
and induced cAMP signaling from intracellular compartments. The differences are likely a result 
of differences in how the peptides activate KOR, as opposed to peptide stability. Our results 
show that seemingly redundant opioid peptides, which activate receptors on the surface to similar 
levels, can drive spatially and temporally different signaling outcomes by differentially sorting 
receptors to distinct endosomal compartments after internalization. 
 
2.2 Results 
To examine activation and internalization of KOR by Dynorphin peptides we first focused 
on four physiologically relevant endogenous peptides – Dynorphin A17 (Dyn A), Dynorphin A8 
(Dyn A8), Dynorphin B (Dyn B), and a-neoendorphin (a-neo). These peptides differ mainly in 
their length and C-terminal peptide sequence (Figure 2.1A). We carried out our studies using 
neuroendocrine PC-12 cells stably expressing KOR tagged with a pH-sensitive GFP (SpH-KOR) 
(Sankaranarayanan et al., 2000) that facilitates visualization of agonist-mediated KOR 
trafficking, and CHO cells stably expressing Flag epitope tagged KOR (CHO-KOR). Consistent 
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with previous findings, we find that in these cells Dyn A, Dyn A8, Dyn B, and a-neo bind KOR 
at relatively comparable affinities (Table 1).  
Next, we measured the inhibition of cAMP levels and KOR endocytosis induced by these 
peptides. Dose–response curves with Dyn A and Dyn B in SpH-KOR cells showed maximal 
inhibition ~1 mM (Supplemental Figure 2.1A). At this concentration, Dyn A8 and a-neo 
inhibited whole cell cAMP to levels comparable to that of Dyn A and Dyn B (Figure 1B). 
Measurement of cell surface levels of KOR by ELISA show that Dyn A and Dyn B endocytose 
the receptor to a similar extent in SpH-KOR cells and in CHO-KOR cells (Supplemental Figure 
2.1B and C; Gupta et al., 2016), with maximal endocytosis at ~1 mM. Examination of surface 
SpH-KOR fluorescence by live cell imaging using Total Internal Reflection Microscopy (TIR-
FM) shows similar extent of agonist-mediated KOR clustering into endocytic domains and 
receptor endocytosis by the four Dynorphin peptides (1 mM) (Figure 2.1C and D). Together 
these results indicate that different Dynorphin peptides activate KOR and induce KOR 





Figure 2.1 . Initial activation and internalization of KOR by Dynorphins are comparable.  
(A) Schematic of the regions of Pro-dynorphin from which Dynorphin A8 (Dyn A8), Dynorphin 
A (Dyn A), Dynorphin B (Dyn B), and α-neoendorphin (α-neo) peptides are generated, showing 
that Dyn A and Dyn B are processed from adjacent regions. (B) Dyn A8, Dyn A, Dyn B, and α-
neo (1 μM) inhibit intracellular cAMP levels to a similar extent in PC12 cells stably expressing 
SpH-KOR. Values were normalized to basal cAMP measurements in the absence of peptide, 
which were set as 100% (mean ± SEM shown). (C) Representative TIR-FM images of PC12 
cells stably expressing SpH-KOR treated with Dyn A8, Dyn A, Dyn B, and α-neo (1 μM) show 
roughly similar agonist-mediated receptor clustering at the cell surface following 1 min 
treatment. Scale bar = 2 µm. (D) Quantitation of the loss of surface SpH-KOR fluorescence, as 
an index of internalization, after 5 min of treatment with each peptide (1 μM), normalized to 
surface fluorescence before agonist treatment, show similar levels of internalization for all four 
peptides (mean ± SEM shown, Dyn A: n = 10 cells; Dyn B: n = 10 cells; Dyn A8: n = 10 cells; 




Supplemental Figure 2.1  
 
 
Supplemental Figure 2.1. Ligand-mediated decreases in intracellular cAMP levels and 
endocytosis of KOR saturates at 1 µM for Dyn A and Dyn B.  
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(A) Dyn A- and Dyn B-mediated decreases in intracellular cAMP levels were measured by 
carrying out doseresponse curves (0–10 µM) in PC12 cells stably expressing SpH-KOR treated 
for 30 min at 37°C. (B) Dyn A- and Dyn B-mediated changes in surface receptor levels were 
measured by ELISA by carrying out dose–response curves (0–10 µM) in PC12 cells stably 
expressing SpH-KOR treated for 30 min at 37°C. (C) Dyn A- and Dyn B-mediated changes in 
surface receptor levels were measured by ELISA by carrying out dose–response curves (0–10 
µM) in CHO cells stably expressing Flag-KOR treated for 60 min at 37 °C. 
 
We next examined if different Dynorphins selectively regulate the fate of KOR after initial 
activation and internalization, by adapting a discrete-event imaging method to quantitate the rate 
of individual KOR recycling events over unit time. SpH-KOR fluorescence is quenched in acidic 
endosomal compartments and is rapidly dequenched when receptors recycle back to the cell 
surface and are exposed to the extracellular media. This dequenching can be visualized as single 
events using Total Internal Reflection Fluorescence microscopy (TIR-FM), where the recycling 
events appear as distinctive sudden spikes in fluorescence followed by an exponential decay as 
the receptors diffuse on the cell membrane (Figure 2.2A–C). This method allows us to quantitate 
individual recycling events in the same cells over time without the confounding effects of 
continuing endocytosis (Kunselman et al., 2019). When the number of SpH-KOR recycling 
events were quantitated and normalized to time and cell area, a significantly higher number of 
recycling events was seen 5 min after Dyn B-induced KOR internalization , compared to Dyn A, 
Dyn A8, or a-neo (Figure 2.2D).  
To test whether this increase in the rate of discrete recycling events corresponded to an 
increase in receptor levels at the cell surface, we measured ensemble changes in surface KOR 
levels by two different methods – whole-cell fluorescence and ELISA-based methods. We 
focused on Dyn A and Dyn B as a highly relevant and interesting pair, as both are processed 
from adjacent regions of prodynorphin and are often co-expressed in physiologically relevant 
brain regions (Nikoshkov et al., 2005; Corder et al., 2018). When SpH-KOR fluorescence was 
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followed by live confocal imaging, surface fluorescence decreased after Dynorphin addition, as 
was expected with receptor internalization. The fluorescence decrease reached a plateau at 10 
min, suggesting an equilibrium between endocytosis and recycling at this time point (Figure 
2.2E). When agonist was removed by washing out the media and replacing with fresh media 
containing antagonist (naltrexone; 10 mm), to specifically measure recycling without the 
contribution of endocytosis, the fluorescence recovery rate was higher with Dyn B than with Dyn 
A at the 30 min time point (Figure 2.2F and G).  
A potential reason for the differences we observe could be differences in the rate of 
proteolytic degradation of the peptides (Mzhavia et al., 2003; Fricker et al., 2020). Therefore, we 
directly tested whether inhibiting proteolysis abolishes the difference between Dyn A and Dyn B. 
We first used a protease inhibitor cocktail in the media to inhibit general proteolysis. When 
discrete recycling events were quantitated as in Figure 2D, Dyn B showed a higher number of 
KOR recycling events even in the presence of protease inhibitors (Supplemental Figure 2.2A). 
When the recovery of surface KOR levels after agonist washout were measured by an 
independent ELISA-based method, Dyn B-treated cells showed a higher rate of recovery 
compared to Dyn A, even in the presence of protease inhibitors (Figure 2.2H). These 
experiments indicate that differences in general proteolysis of the peptides did not contribute to 
the increased KOR recycling we observe with Dyn B. Because Dyn B, but not Dyn A, can be 
cleaved by Endothelin Converting Enzyme 2 (ECE2) in vitro, we next tested whether this 
differential proteolysis by ECE2 could contributes to the differences between Dyn A and Dyn B-
induced KOR recycling. We used S136492, which inhibits ECE2 relatively selectively in vitro in 
purified systems (Mzhavia et al., 2003), to test whether ECE2 activity was required for Dyn B to 
drive increased recycling. S136492 significantly reduced recycling for both Dyn A and Dyn B, 
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indicating that the differences in trafficking between Dyn B and Dyn A cannot be explained 
solely by ECE2 sensitivity (Supplemental Figure 2.2B). Together, these results suggest that 
intrinsic differences between Dyn A and Dyn B contribute to differences in KOR recycling when 
activated by these peptides.  
Because KOR did not recycle efficiently when activated by Dyn A, we next asked whether 
Dyn A-activated KOR was sorted into the degradative pathway. To test this, PC12 cells 
expressing SpHKOR were pretreated with cycloheximide (3 mg/ml) 2 hr before agonist addition 
to inhibit any new protein synthesis and to measure agonist-mediated turnover of KOR. Total 
KOR levels were determined through immunoblotting, after Dyn A or Dyn B treatment for 30 
min or 2 hr (Figure 2.2I). When total receptor levels were quantified, 2 hr treatment with Dyn A 
caused a loss of 50% of KOR, while Dyn B treatment caused no loss (Figure 2.2J). These results 
suggest that, after endocytosis, Dyn A preferentially sorts KOR into the degradative pathway, 















Figure 2.2. The post-endocytic fate of KOR is determined by the specific Dynorphin that 
activates it.  
(A) Frames from a time lapse movie of a representative region of a PC12 cell stably expressing 
SpH-KOR (SpH-KOR cells) shown in (B), treated for 5 min with Dyn B (1 μM) and imaged in 
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TIR-FM, showing two examples of exocytic events (white arrows in A) associated with KOR 
recycling. (C) Fluorescence traces of the two exocytic events, arbitrary units, showing a 
characteristic abrupt increase in maximum fluorescence intensity followed by exponential decay. 
(D) Quantitation of the number of exocytic events/µm2/min showing a significant increase for 
Dyn B compared to the other peptides (mean ± SEM, **p<0.01, ****p<0.0001 in multiple 
comparisons after ANOVA, n = 14, 39, 52, and 33 cells for α-neo, Dyn A, Dyn B, and Dyn A8, 
respectively). (E) Ensemble SpH-KOR surface fluorescence measured over time using confocal 
microscopy shows a decrease in fluorescence upon agonist addition because of quenching of 
internalized SpH-KOR, and an increase upon peptide washout as receptors recycle to the surface 
and SpH-KOR is dequenched. (F) Quantification of change in ensemble surface fluorescence 
over 30 min following treatment with Dyn A or Dyn B (1 μM), normalized to fluorescence 
before agonist addition, showing the loss during endocytosis and increase during recycling. (G) 
Quantitation of the amount of SpH-KOR recycled, normalized to the amount endocytosed after 
Dyn A or Dyn B treatment B (1 μM), shows that a higher amount of receptor is recycled after 
Dyn B washout (mean ± SEM, ****p<0.0001 by Mann–Whitney; n = 33 and 30 fields for Dyn 
A and Dyn B, respectively). (H) Recycling of SpH-KOR to the cell surface after treatment with 
100 nM Dyn A or Dyn B measured by ELISA shows a much higher rate and extent of recycling 
after Dyn B washout. (I) Representative immunoblot of total receptor levels in SpH-KOR cells 
treated with cycloheximide (3 µg/ml) for 2 hr prior to Dyn A or Dyn B treatment (1 μM) for the 
indicated times show receptor loss after 120 min of Dyn A but not Dyn B treatment. GAPDH is 
used as a control. (J) Quantification of total receptor levels normalized to untreated control cells 
under each condition (**p<0.01 by post hoc comparison after two-way ANOVA; n = 5). 
 




Supplemental Figure 2.2. The differences in KOR recycling between Dyn A and Dyn B 
cannot be explained entirely by peptide degradation.  
(A) Quantitation of the number of exocytic events/μm2/min in SpH-KOR PC12 cells shows a 
significantly higher number of events for Dyn B compared to Dyn A (1 µM) in the continued 
presence of protease inhibitors (***p<0.001, in unpaired t-test n = 9 and 6 cells for Dyn B and 
Dyn A, respectively). (B) Quantitation of the percent change of exocytic events in PC12 SpH-
KOR cells treated with Dyn A or Dyn B in the presence or absence of 10 µM phosphoramidon 
(PHOS), a neprilysin/ECE inhibitor, or 20 μM S136492, an ECE2 inhibitor (ECE2 inh). Both 
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inhibitors decreased % events/minute for both Dyn A and Dyn B, suggesting that ECE2 
inhibition on its own cannot explain the differences between the peptides. 
Considering the emerging importance of spatial encoding in diversifying the outcomes of 
GPCR signaling (Eichel and von Zastrow, 2018; Weinberg et al., 2019; Hanyaloglu, 2018), we 
next asked whether Dyn A or Dyn B generated distinctive intracellular localization patterns of 
KOR at steady state. Because Dyn A drove KOR degradation, we first tested whether Dyn A-
activated KOR was differentially localized to the late endosomal pathway. When PC12 cells 
expressing FLAG-KOR and Rab7-GFP, to mark the late endocytic pathway, were treated with 1 
mM Dyn A for 20 min and imaged live, KOR colocalized predominantly with Rab7 (example in 
Figure 2.3A). To quantitate the distribution of KOR in the endosomal pathway more 
comprehensively, we treated cells expressing SpH-KOR with 1 mM Dyn A or Dyn B for 20 min, 
and fixed and stained for APPL1 (very early endosomes), EEA1 and Rab5 (early endosomes), 
Rab11 (recycling endosomes), Rab7 (late endosomes), and Lamp1 (lysosomes), as markers for 
the biochemically distinct compartments along the early, recycling, and late endosomal pathway. 
Using automated object-picking, we then quantitated the fraction of KOR that colocalized with 
each endosomal marker under these conditions. KOR localized mainly to compartments marked 
by Rab7 and Lamp1 when activated by Dyn A, but to compartments marked by EEA1, Rab5, 
and Rab11 when activated by Dyn B (Figure 2.3B and C). These results show that KOR is 
concentrated in different endosomal compartments based on the Dynorphin that activates it.  
The agonist-selective localization of KOR to specific endosomes raised the exciting 
possibility that different Dynorphins could generate distinct subcellular spatial patterns of KOR 
signaling. To test this possibility, we combined conformation-selective biosensors and high-
resolution imaging of FLAG-KOR to ask whether KOR was active in endosomes. A nanobody 
(Nb39) that specifically recognizes the active conformation of KOR (Che et al., 2018), when co-
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expressed with FLAG-KOR in PC12 cells, localized efficiently to endosomes that also contained 
Dyn A-activated KOR. In contrast, Nb39 localized less to endosomes containing Dyn B-
activated KOR (Figure 2.3D and E). When the fraction of total number of KOR endosomes/cell 
that colocalized with Nb39 was quantitated by analyzing 3D stacks, endosomes containing Dyn 
A-activated KOR recruited Nb39 at a significantly higher level (Figure 2.3F and G), suggesting 
that KOR was in an active conformation in the endosomes specifically after activation by Dyn A. 
Nb39 recruitment to endosomes required KOR endocytosis, as recruitment was abolished when 
cells were treated with agonist in the presence of 40 µM Dyngo4A, an endocytosis inhibitor 
(Supplemental Figure 2.3A and B). To directly examine whether Dyn A-activated KOR in 
lysosomes was in an active conformation, we used three-color live cell imaging of FLAG-KOR, 
Nb39, and LysoTracker. In cells treated with 1 µM Dyn A, a subset of KOR endosomes 
colocalized with both Nb39 and Lysotracker. In cells treated with 1 mM Dyn B, however, 
virtually no KOR endosomes colocalized with both Nb39 and Lysotracker (Figure 2.3H). When 
the colocalization was quantitated in Dyn A-treated cells, ~15% of all KOR endosomes 
colocalized with both markers, suggesting that a subset of Dyn A-activated KOR in the lysosome 
was in the active conformation (Figure 2.3I). In contrast, in cells treated with 1 mM Dyn B, 
virtually no KOR endosomes colocalized with both Nb39 and Lysotracker (Figure 2.3H).  
To test whether the subset of Dyn A-activated KOR in the active conformation in late 
endosomes and lysosomes was capable of signaling, we measured cAMP inhibition under 
conditions where the agonist was washed out to avoid continued signaling from the surface. 
Twenty-five minutes after agonist washout, Dyn A-activated KOR was still localized 
predominantly to Rab7-labeled late endosomal compartments, while Dyn B-activated KOR was 
localized predominantly to Rab11-labeled recycling endosomes (Supplemental Figure 2.3C–H). 
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This distribution was comparable to that observed in the continued presence of agonist, and at 
this time point, there was little to no KOR degradation (Figure 2.2I and J). Strikingly, Dyn A, but 
not Dyn B, caused sustained decrease in cAMP levels under conditions where the majority of 
KOR was in late endosomes and lysosomes (Figure 2.3J). Together, our results suggest that Dyn 
A, but not Dyn B, specifically coordinates activation and cAMP inhibition by KOR in late 




Figure 2.3. Dyn A selectively drives KOR signaling from late endosomal compartments.  
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(A) Representative image of a PC12 cell expressing FLAG-KOR and Rab7-GFP, treated with 1 
µM Dyn A for 20 min. Yellow arrows denote KOR endosomes that colocalize with Rab7. (B) 
SpH-KOR cells treated with 1 μM Dyn A for 20 min were fixed and processed for 
immunofluorescence with the noted markers. Quantitation, across multiple cells, of the 
percentage of KOR containing endosomes that colocalize with each of the endosomal markers is 
noted. KOR primarily localizes in Rab7 and Lamp1 positive late endosomes after Dyn A (n = 8, 
10, 9, 11, 20, and 17 cells for APPL1, EEA1, Rab5, Rab11, Rab7, and Lamp1, respectively). (C) 
A similar quantitation of immunofluorescence images after Dyn B treatment (1 μM for 20 min) 
shows that KOR localizes less with late endosomes, and more with markers of early/recycling 
endosomes (n = 18, 16, 15, 18, 23, and 29 cells for APPL1, EEA1, Rab5, Rab11, Rab7, and 
Lamp1, respectively). (D) Representative images of PC12 cells expressing FLAG-KOR and 
Nb39, imaged live after treatment with 1 µM Dyn A or Dyn B for 20 min. Yellow arrows in Dyn 
A show KOR endosomes that recruited Nb39, while cyan arrows in Dyn B show KOR 
endosomes that do not show obvious recruitment of Nb39. (E) Linear profile plots of 
fluorescence of KOR and Nb39, measured along lines drawn across regions of the cell with KOR 
endosomes after treatment with 1 μM Dyn A or Dyn B for 20 min, show that Nb39 fluorescence 
increases along with KOR in Dyn A, but less noticeably with Dyn B. (F) Ratios of integrated 
fluorescence of Nb39:KOR in endosomes identified by 3D object analysis show higher amounts 
of Nb39 relative to KOR in Dyn A-treated cells (****p<0.0001 by Mann–Whitney, n = 766 and 
800 endosomes for Dyn A and Dyn B, respectively). (G) Quantitation of the percentage of KOR 
endosomes per cell with a noticeable increase in Nb39 fluorescence above background shows a 
higher fraction of KOR endosomes recruited Nb39 in 1 µM Dyn A-treated cells (***p<0.001 by 
Mann–Whitney, n = 11 and 14 cells for Dyn A and Dyn B, respectively). (H) Representative 
images of PC12 cells expressing FLAG-KOR and Nb39 and labeled with LysoTracker imaged 
live after treatment with 1 μM Dyn A or Dyn B for 20 min. Yellow arrows in Dyn A show KOR 
endosomes that recruited Nb39 that were also labeled with Lysotracker, while cyan arrows in 
Dyn B show KOR endosomes that do not show obvious labeling with Nb39 and Lysotracker. (I) 
The average composition of total KOR endosomes that are positive for ±Nb39 and ±Lysotracker 
after 20 min treatment with Dyn A (1 μM). n = 10 cells. −Lyso/−Nb39 = 23.4 ± 8.1%; 
−Lyso/+Nb39 = 38.4% ± 17.4%; +Lyso/−Nb39 = 23.7 ± 11.4%; +Lyso/+Nb39 = 14.6 ± 5.1%. 
(J) cAMP levels after initial Dynorphin treatment (1 μM) for 5 min, washout for 25 min, or a 
Dynorphin rechallenge (1 μM) at end of the washout, show comparable initial cAMP inhibition 









Supplemental Figure 2.3 
 
Supplemental Figure 2.3. Differential receptor sorting between Dyn A and Dyn B persists 
even after agonists are washed out from the surface.  
(A) Representative images of PC12 cells expressing FLAG KOR treated with Dyn A in the 
presence of 40 µM Dyngo4A for 30 min to block endocytosis. KOR (magenta in merge) 
fluorescence is restricted to the surface with little endosomal KOR after 20 min Dyn A (1 µM), 
and no recruitment of Nb39 (green) to internal endosomes. (B) A similar Dyngo4a treatment 
blocked recruitment of Nb33 to internal endosomes after 20 min Dyn A (1 µM). (C) 
Representative images of cells labeled live with anti-FLAG antibodies for surface KOR, treated 
for 5 min with 1 µM Dyn A or Dyn B followed by a 25 min washout, then fixed and stained for 
Rab7 to mark late endosomes. (D) Linear profile plots of fluorescence for KOR and Rab7, 
measured along lines drawn across regions of the cells in C, show that Rab7 fluorescence spikes 
correlate with KOR spikes in Dyn A, but less with Dyn B. (E) Quantitation of the percentage of 
KOR endosomes/cell colocalizing with Rab7 shows a higher fraction of KOR endosomes 
recruited Rab7 in Dyn A-treated cells (***p<0.001 by Mann–Whitney, n = 10 and 11 cells for 
Dyn A and Dyn B, respectively). (F) Representative images of cells labeled live with anti-FLAG 
antibodies for surface KOR, treated for 5 min with 1 µM Dyn A or Dyn B followed by a 25 min 
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washout, then fixed and stained for Rab11 to mark recycling endosomes. (G) Linear profile plots 
of fluorescence for KOR and Rab11, measured along lines drawn across regions of the cells in F, 
show that Rab11 fluorescence increases along with KOR in Dyn B, but less noticeably with Dyn 
A. (H) Quantitation of the percentage of KOR endosomes/cell colocalizing with Rab11 shows a 
higher fraction of KOR endosomes recruited Rab11 in Dyn B-treated cells (**p<0.01 by Mann–
Whitney, n = 9 and 10 cells for Dyn A and Dyn B, respectively). 
 
Importantly, this Dynorphin-selective coordination of KOR recycling and endosomal 
activation was conserved in striatal neurons. To directly measure KOR recycling, E18 rat 
primary embryonic striatal neurons were transfected with SpH-KOR, and individual recycling 
events were imaged using TIRFM. The number of individual exocytic events, when quantified 
per minute and normalized to cell area, was significantly lower in neurons treated for 30 min 
with 1 mM Dyn A compared to Dyn B (Figure 2.4A). This suggested that Dyn B, but not Dyn A, 
preferentially sorted KOR to recycling endosomes in neurons. We directly tested this by 
detecting the steady-state localization of KOR in endosomes after Dyn A or Dyn B treatment. 
KOR colocalized predominantly with Rab7 when activated by Dyn A, and with Rab11 when 
activated by Dyn B (Figure 2.4B and C). To test whether this differential localization correlated 
with differential location-based activation of KOR in endosomes, we expressed Nb33, a distinct 
nanobody that recognizes the active conformation of opioid receptors (Manglik et al., 2017), 
fused to GFP in neurons. Endosomes containing Dyn A-activated KOR recruited Nb33, while 
endosomes containing Dyn B-activated KOR recruited Nb33 to a noticeably lesser extent. This 
recruitment was readily apparent in dendritic projections, where endosomes were distinctly 
visible (Figure 2.4D). The percentage of KOR endosomes that recruited Nb33 was significantly 
higher for Dyn A-activated KOR than for Dyn B (Figure 2.4E), showing that dynorphin-selective 









Figure 2.4. Dyn A-specific late endosomal localization and signaling is conserved in striatal 
neurons.  
(A) The number of discrete exocytic events quantitated in rat medium spiny neuron (MSN) 
expressing SpH-KOR shows increased recycling for 1 μM Dyn B compared to Dyn A 
(***p<0.001, n = 8 cells). (B) Quantification of the percentage of KOR endosomes colocalized 
with Rab7 in MSN expressing SpH-KOR treated with 1 μM Dyn A or Dyn B for 30 min 
(**p<0.01, n = 5 cells for both). (C) Quantification of the percentage of KOR endosomes 
colocalized with Rab11 in MSN expressing SpH-KOR treated with 1 μM Dyn A or Dyn B for 30 
min (**p<0.01, n = 5 and 9 cells for Dyn A and Dyn B, respectively). (D) Colocalization of 
FLAG-KOR and Nb33-GFP in the soma and in dendrites of MSNs treated with 1 μM Dyn A for 
30 min, seen by confocal microscopy. Yellow arrows show KOR endosomes that recruit Nb33. 
(E) Quantitation of the percentage of KOR endosomes/cell with a noticeable increase in Nb33 
fluorescence above background shows that a higher fraction of KOR endosomes recruited Nb33 
in Dyn A-treated cells (1 μM for 30 min; ***p=0 < 0.001, n = 10 cells). All p-values were from 





Supplemental Figure 2.4 
 
 
Supplemental Figure 2.4. mTOR signaling does not show significant differences between 
Dyn A and Dyn B.  
(A) Representative blots showing phosphorylated (pS6K) and total (tS6K) S6K levels in PC12 
cells stably expressing SpH-KOR treated with 1 µM Dyn A or Dyn B for 5 and 20 min. (B) 
Quantitation of the fold change over Ctrl baseline to measure mTOR activation: pS6K signal 




Together, our results reveal an unanticipated difference between physiologically important 
endogenous opioid peptides in encoding the subcellular spatial patterns of KOR signaling. 
Peptidases localized to endosomes, like endothelin-converting enzymes (ECEs) may provide 
another level of regulation for agonist-dependent KOR trafficking (Padilla et al., 2007; 
Roosterman et al., 2007; Gupta et al., 2015). However, our results do not suggest that ECE 
peptide-sensitivity is the only or primary factor that determines agonist-dependent KOR 
localization (Supplemental Figure 2.2). Ubiquitination of KOR may also regulate its ability to 
traffic to and signal from late endosomal and lysosomal compartments (Li et al., 2008; Henry et 
al., 2011; Dores and Trejo, 2019).  
The exact mechanism by which KOR is localized to different compartments is not clear. 
Because the post-endocytic sorting of GPCRs is usually mediated by specific interactions of the 
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unstructured cytoplasmic tail of the receptors with trafficking proteins, KOR sorting probably 
involves interactions with PDZ-interacting protein NHERF1/EBP50 (Liu-Chen, 2004). In this 
context, different Dynorphin peptides could lock KOR into conformations that selectively allow 
or inhibit interactions with trafficking and signaling proteins, essentially defining the receptor 
interactome in an agonist-specific manner. This conformational lock could require the presence 
of the ligand that is co-internalized with the receptor, although an exciting possibility is that the 
ligands provide a ‘conformational memory’ to KOR that is sustained through the endocytic 
trafficking pathway. At present it is not clear what could provide such a conformational memory. 
It is possible that different Dynorphins could cause agonist specific post-translational 
modifications, which is a general emerging theme for opioid receptors (Chiu et al., 2017; Mann 
et al., 2019). In any case, the differential subcellular localization and trafficking of KOR by two 
physiologically important ligands that we show here are important to underscore the 
physiological relevance of receptor sorting, which has been studied largely using receptor 
mutants or by depleting key components of the trafficking machinery (Bowman et al., 2016; 
Weinberg et al., 2019; Zhao et al., 2013; Sposini et al., 2017).  
One striking aspect of our results is that Dyn A-bound KOR activates Gi in the late 
endosomal pathway on its way to being degraded. This is surprising because early endosomes 
are the main compartments that support endosomal signaling for most other canonical GPCRs. 
For example, other Gi-coupled receptors such as the mu opioid receptor can exist in an active 
conformation in earlier endosomal compartments (Stoeber et al., 2018). Internalization is 
required for sustained inhibition of cAMP for many receptors, such as for the class B S1P 
receptor (Willinger et al., 2014). However, Gi is likely present on late endosomal and lysosomal 
compartments, as cannabinoid receptors trafficking from the Golgi can activate Gi on lysosomes 
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(Rozenfeld and Devi, 2008). Further, the binding of peptides to opioid receptors does not change 
dramatically at lower pH (Gupta et al., 2015). Therefore, it is possible that Gi could be activated 
at multiple endosomal compartments based on the specific opioid receptor and ligand, leading to 
distinct early and late phases of endosomal signaling.  
Post-translational modifications such as phosphorylation or ubiquitination could provide 
regulatory handles for this late phase of signaling. For example, three lysine residues on the C-
terminus of KOR are required for normal levels of degradation of KOR, but not for 
internalization from the surface (Li et al., 2008). Ubiquitination, however, plays complex roles in 
receptor trafficking and signaling at the endosome, controlling transport of receptors to 
lysosomes, entry of receptors into intralumenal vesicles, and recruitment of signaling scaffolds 
that could initiate non-canonical signaling pathways (Patwardhan et al., 2021). In this context, 
Dyn A-activated KOR could also activate alternate pathways, such as mTOR signaling, on late 
endosomes and lysosomes. Interestingly, mTOR signaling is involved in potentially deleterious 
effects of KOR, leading to efforts to generate agonists bypassing this signaling pathway (Che 
and Roth, 2018; Liu et al., 2018; Liu et al., 2019). However, under the conditions we tested, we 
did not see a significant increase in p70S6 phosphorylation, as a readout for mTOR activation, 
upon activation of KOR with either Dyn A or Dyn B. This could potentially be due to the high 
baseline of p70S6 phosphorylation in the PC12 cells (Supplemental Figure 2.4). However, it is 
possible that KOR could activate mTOR signaling from late endosomes or lysosomes in a subset 
of neurons yet to be identified, that could mediate aversive effects of KOR.  
Physiological systems could leverage receptor sorting to fine-tune both spatial and 
temporal aspects of GPCR signaling. KOR is activated by many opioid peptides that are 
generated from multiple precursor peptides, some of which bias signaling from the cell surface to 
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different outputs (Gomes et al., 2020). Our results suggest that, even for peptides where there are 
no obvious differences in surface signaling, there are differential effects in endocytic sorting and 
signaling from endosomes. Receptor sorting in cells is a dynamic and incomplete process. The 
fractions of receptors we see at steady state likely represent an equilibrium of many rounds of 
rapid iterative sorting as the endosome matures, where only a small fraction is recycled back to 
the surface in the case of Dyn A, while a large fraction is recycled in the case of Dyn B. Because 
Dyn A drives little KOR to recycle and promotes endosomal KOR activation, the net effect 
would be to cause a sustained cAMP inhibition from endosomes after a single exposure. Because 
Dyn B drives KOR recycling and induces endosomal signaling only to small amounts, the net 
effect would be short-lived cAMP inhibition primarily from the surface. On the other hand, the 
rapid recycling and resensitization caused by Dyn B would sensitize cells to repeated pulses of 
ligand release, unlike with Dyn A. This difference in steady-state localization, however, is 
enough to cause a difference in endosomal receptor activation and cAMP signaling, suggesting 
that small differences in steady-state localization can cause relevant changes in signaling.  
Whether these different Dynorphins are always co-released in the nervous system, or 
whether different brain regions selectively release specific Dynorphins, is still unclear. Dyn A 
and Dyn B are generated from prodynorphin likely in the late stages of dense core vesicle 
maturation and could be predominantly co-released, but there could be mechanisms that actively 
segregate or selectively release individual Dynorphins. In the case of co-released peptides, it is 
possible that one or more of the peptides could be dominant in dictating the conformational 
states in which receptors spend most of their time, in which case the signaling and trafficking 
fates would be determined primarily by these dominant peptides. In any case, our results that 
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highly related opioid peptides regulate spatial encoding of KOR suggest an unanticipated layer 
of granularity to the anatomical and functional maps of the brain. 
 
 
2.4 Materials and Methods 
Reagents, constructs, and cells  
Dynorphin A17 (Dyn A), Dynorphin B13 (Dyn B), Dynorphin A (Dyn A8), and a-
neoendorphin (a-neo) were purchased from Tocris Bioscience and/or Phoenix Pharmaceuticals. 
Naltrexone, protease inhibitor cocktail (Cat. No. P2714), anti-Flag M2 antibody (Cat. No. 
F3165) were purchased from Sigma Aldrich (St. Louis, MO). Anti-APPL1, -EEA1, -Rab5, -
Rab11, -Rab7, -Lamp1 rabbit monoclonal antibodies were purchased from Cell Signaling 
Technology. Anti-GFP rabbit polyclonal antibodies (Cat. No. A10260) were from Thermo Fisher 
Scientific. Nb39 and Nb33 constructs were provided by Dr. Bryan Roth (UNC Chapel Hill) and 
Dr. Mark von Zastrow (UCSF) respectively. Cell lines used were validated, and cells were 
purchased from ATCC. Cells in the lab are routinely tested for mycoplasma contamination. 
Stable non-clonal PC12 cells expressing KOR N-terminally tagged with superecliptic phluorin 
(SpH) (SpH-KOR cells) were selected in puromycin (Gibco) and grown in F12K media 
supplemented with 10% horse serum and 5% fetal bovine serum (Gibco) in collagen coated 
flasks. PC12 cells were also transiently transfected with KOR fused to FLAG on its N-terminus 
using Lipofectamine 2000 as per manufacturer’s protocol (ThermoFisher). Transfected cells 
were imaged 2–3 days after transfection. CHO cells stably expressing Flag epitope tagged KOR 
generated as described previously (Gupta et al., 2016) were grown in F12 media supplemented 
with 10% fetal bovine serum and 1% penicillin–streptomycin. E18 rat striatal neurons were 
obtained from BraintBits LLC and cultured on poly-d-lysine (Sigma) coated coverslips for 1 
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week in Neurobasal media (Gibco) supplemented with B27 (Gibco), 1% Glutamax (Gibco), and 
1% penicillin–streptomycin (Gibco) before transfection with SpH-KOR or Flag-KOR and Nb33-
GFP using Lipofectamine 2000 as per manufacturer’s protocol (ThermoFisher). Antibodies used 
are listed below. 
 
Displacement binding assays  
Displacement binding assays were carried out using membranes from PC12 cells stably 
expressing SpH-KOR (SpH-KOR cells) (100 mg) and CHO-KOR (15 mg) cells. Membranes 
were prepared as described previously (Gomes et al., 2003). Displacement binding assays were 
carried out as described previously (Gomes et al., 2004; Gomes et al., 2011) by incubating 
membranes with [3H] diprenorphine (3 nM) without or with different concentrations (1012to 105 
M) of Dyn A8, Dyn A17, Dyn B13, or a-neo-endorphin in 50 mM Tris-Cl buffer pH 7.4 
containing 100 mM NaCl, 10 mM MgCl2, 0.2 mM EGTA, and protease inhibitor cocktail 
(Sigma-Aldrich; cat No. P2714) for 1 hr at 37˚ C. Non-specific binding was determined in the 
presence of 10 mM cold diprenorphine. Specific Bound Counts obtained in the absence of 
peptides was taken as 100%. Data presented are mean ± SE of three independent experiments in 
triplicate.  
 
Live cell imaging  
Cells were plated onto poly-D-lysine (Sigma) coated 25 mm coverslips. Cells were 
imaged 2 days later in Leibovitz L15 imaging medium (Gibco) and 1% fetal bovine serum at 
37˚C in a CO-controlled imaging chamber, using a Nikon Eclipse Ti automated inverted 
microscope with a 60 or a 100 1.49 N.A. TIRF objective or a 20 0.75 N.A. objective. Images 
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were acquired with an iXon +897 electron-multiplying charge-coupled device camera with a 
solid state laser of 488 nm or 647 nm as a light source. Images were analyzed using FIJI 
(Schindelin et al., 2012).  
 
Quantification of individual recycling events  
PC12 cells stably expressing SpH-KOR (SpH-KOR cells) were treated with KOR 
agonists: Dyn A17, Dyn B13, Dyn A8, or a-neo endorphin (1 mM) for 5 min to induce receptor 
clustering and internalization at 37˚C. Receptor clustering was visualized using TIRF 
microscopy. Images were acquired every 3 s for a total of 5 min. Following internalization, a 
recycling movie was recorded at 10 Hz for 1 min in TIRF. The number of exocytic recycling 
events were manually scored in FIJI (Fiji Is Just Image J) to determine the recycling rate for each 
agonist. Recycling events were counted throughout the 1 min movie and the total number of 
events were normalized by the cell area to determine a recycling rate. Recycling events were also 
recorded using the same method in primary striatal rat medium spiny neurons transfected with 
the SpH-KOR plasmid. Recycling movies were taken 30 min after agonist addition in neurons. 
Statistical significance was determined using a one-way ANOVA 
 
Ensemble recycling assay  
Receptor surface levels were measured in PC12 cells stably expressing SpH-KOR (SpH-
KOR cells) by using confocal microscopy on a 20 objective and 488 nm laser. Images were 
collected in 30 s intervals across 20 different cell fields. After 2 min of baseline an agonist (1 
mM Dyn A17 or Dyn B13) was added to imaging media. Following agonist addition, images 
were collected for 15 min. After 15 min, agonist was removed, and the imaging media was 
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replaced with fresh media containing antagonist (naltrexone; 10 mm). Images were then 
collected for another 15 min. Fluorescence intensities were corrected by a background threshold 
and normalized by the average fluorescence of the baseline frames before agonist treatment. 
Surface fluorescence analysis was conducted using an ImageJ Macro automated script (National 
Institutes of Health) (Weinberg et al., 2019). Fluorescence recovery/loss ratios after washout 
were quantified by normalizing the fluorescence values after washout to the total fluorescence 
lost before washout. Cell fields that did not respond to Dynorphin treatment were excluded from 
analysis. Statistical significance was determined by using Student’s paired t-test comparing the 
endpoints between agonist treatment.  
 
ELISA internalization assays  
CHO cells expressing Flag-epitope tagged KOR (CHO-KOR cells) or PC12 cells stably 
expressing SpH-KOR (SpH-KOR cells) were seeded in complete growth media into 24-well 
plates (2 105 cells per well). Next day, cells were rinsed with PBS followed by labeling with 
mouse anti-Flag antibodies for CHO-KOR cells or chicken anti-GFP antibodies for SpH-KOR 
cells (1:1000 in PBS containing 1% BSA) for 1 hr at 4˚C, followed by treatment with 0–10 mM 
of Dyn A or Dyn B in growth media containing protease inhibitor cocktail (Sigma-Aldrich; Cat. 
No. P2714) for 60 min at 37˚C. Cells were briefly fixed (3 min) with 4% paraformaldehyde 
followed by three washes (5 min each) with PBS, and incubation with anti-mouse or anti-chicken 
antibody coupled with horse-radish peroxidase (1:1000 in PBS containing 1% BSA) for 90 min 
at 37˚C. Cells were washed three times with 1% BSA in PBS (5 min each wash), and color was 
developed by the addition of the substrate o-phenylenediamine (5 mg/10 ml in 0.15 M citrate 
buffer [pH 5] containing 15 ml of H2O2). Absorbance at 490 nm was measured with a Bio-Rad 
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ELISA reader. Values obtained with secondary antibody in the absence of primary antibody were 
taken as non-specific and subtracted from all points. The percentage of internalized receptors 
was calculated by taking total cell surface receptors before agonist treatment for each individual 
experiment as 100% and subtracting percent surface receptors following agonist treatment. Data 
presented are mean ± SE of three independent experiments in triplicate.  
 
ELISA recycling assays  
CHO cells expressing Flag-epitope tagged human KOR (CHO-KOR cells) or PC12 cells 
stably expressing SpH-KOR (SpH-KOR cells) were seeded in complete growth media into 24-
well plates (2 105 cells per well). Next day, cells were rinsed with PBS followed by labeling 
with mouse anti-Flag antibodies for CHO-KOR cells or chicken anti-GFP antibodies for SpH-
KOR cells (1:1000 in PBS containing 1% BSA) for 1 hr at 4˚C, followed by treatment with 100 
nM Dyn A, Dyn B, or BAM-22 in growth media containing protease inhibitor cocktail (Sigma-
Aldrich; Cat. No. P2714) for 30 min to elicit receptor internalization. The cells were washed to 
remove the agonist and incubated with medium without or with the ECE2 inhibitor (S136492, 20 
mM) for 0–120 min to allow for receptor recycling. At the end of the incubation period, cells 
were chilled to 4˚C and then fixed briefly (3 min) with 4% paraformaldehyde followed by three 
washes (5 min each) with PBS and incubation with antimouse or anti-chicken antibody coupled 
with horse-radish peroxidase (1:1000 in PBS containing 1% BSA) for 90 min at 37˚C. Cells were 
washed three times with 1% BSA in PBS (5 min each wash), and color was developed by the 
addition of the substrate o-phenylenediamine (5 mg/10 ml in 0.15 M citrate buffer [pH 5] 
containing 15 ml of H2O2). Absorbance at 490 nm was measured with a Bio-Rad ELISA reader. 
Values obtained with secondary antibody in the absence of primary antibody were taken as non-
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specific and subtracted from all points. % recycled receptors were calculated by subtracting 
receptors at t = 0 (30 min internalization) from each recycling time point; this represents 0% 
recycled receptors. Data presented are mean ± SEM of three independent experiments in 
triplicate. 
 
Immunofluorescence of endosomal markers  
PC12 cells stably expressing SpH-KOR were plated on poly-d-lysine (Sigma Aldrich) 
coverslips and grown for 24–48 hr at 37˚C. Cells were then incubated with different agonists 
(Dyn A, Dyn B, Dyn A8, or a-neo) for 20 min at 37˚C. Cells were then fixed with 4% 
paraformaldehyde (PFA), pH 7.4, for 20 min. Cells were then rinsed with complete PBS twice 
and then blocked in PBS containing calcium, magnesium, with 5% FBS, 5% 1M glycine, and 
0.75% Triton X-100. SpH-KOR cells were then incubated with an antibody for one of the 
endosomal markers for 1 hr. Cells were washed three times with PBS containing calcium and 
magnesium and then labeled with Alexa 647 goat anti-rabbit secondary antibody (1:1000) in a 
blocking buffer for 1 hr. Confocal imaging of cells was performed using spinning disk confocal 
microscope (Andor) and 100 objective. Representative images were taken across 10–20 fields for 
each agonist treatment and endosomal marker. Three biological replicates were performed in 
each condition.  
 
Endosomal KOR colocalization in live cells with nanobodies and lysotracker  
PC12 cells were transiently transfected with FLAG-KOR and Nb39-YFP or (Nb33-GFP). 
Cells were labeled with M1-647 for 10 min prior to imaging 3 days after transfection. Images 
were taken before and after cells were treated with 1 mM Dyn A or Dyn B for 20 min. Confocal 
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imaging of cells was performed using spinning disk confocal microscope (Andor) and 100 
objective. Representative images were taken across 10–20 fields for each agonist treatment. In 
the experiments with Dyngo4A, cells were pretreated with 40 mM Dyngo4a for 30 min prior to 
imaging. In the Lysotracker experiments, cells were labeled with 25 nM Lysotracker-561 for 5 
min prior to imaging.  
 
Endosomal colocalization quantification  
The percent colocalization of the endosomal marker with the total number of receptor 
positive endosomes was determined using an ImageJ Macro: Object.picker (Weinberg, 2020; 
doi.10.5281/ zenodo.3811031) to identify the total number of endosomes containing receptor in 
one channel and determine the colocalization with an endosomal marker in another channel. The 
Image J macro: 3D Object Counter was used as another method of quantification for 
colocalization. Integrated density values for each object detected in both the receptor and 
endosome marker channels were used to determine a ratio of endosomal colocalization by 
dividing the endosomal marker signal by the receptor signal.  
 
Immunoblotting  
PC12 cells stably expressing SpH-KOR were grown in a PDL coated 12-well plate for 2 
days at 37˚C. Cells were treated with cycloheximide (3 mg/ml) for 2 hr before agonist 
incubation. Cells were treated with Dyn A17 or Dyn B13 for 30 min or 2 hr. A non-agonist 
treated well of PC12 cells stably expressing SpH-KOR and a well of PC12 cells not expressing 
SpH-KOR were used as controls. Following agonist treatments, cells were placed on ice and 
rinsed twice with PBS containing calcium and magnesium. Cells were directly lysed in the plate 
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using 2 RSB (Bio-Rad, Hercules, CA). Lysates were placed on ice for 30 min and then sonicated 
in 5 s pulses. Following sonication, lysates were incubated at 37˚C for 1 hr. Lysates were run on 
10% stain-free gels (BioRad), which were then transferred to nitrocellulose membrane overnight. 
Membranes were blocked in 5% milk and then probed with anti-GFP Chicken pAB (Abcam) to 
detect total receptor levels in each condition. Blots were developed using the iBright imager for 
chemiluminescence signal and quantified using FIJI software. Receptor signal for each condition 
was normalized to the no treatment control. Five biological replicates were performed. Statistical 
analysis was performed using two-way ANOVA across time and drug treatment. To test for 
mTOR activation, PC12 cells stably expressing SpH-KOR were grown in a PDL coated 12-well 
plate for 2 days at 37˚C. Cells were starved overnight in serum-free media and then treated with 
1 mM Dyn A or Dyn B for 5 min or 20 min. Cells were placed on ice and rinsed twice with PBS 
containing calcium and magnesium. Cells were directly lysed in the plate using 2 RSB (Bio-Rad, 
Hercules, CA). Lysates were placed on ice for 5 min and then placed at 95˚C for 5 min. Lysates 
were run on 10% stain-free gels (BioRad), which were then transferred to nitrocellulose 
membrane overnight. Membranes were blocked in 5% BSA and then probed with phospho-p70 
S6K (CST) to detect phosphorylated S6K levels in each condition. Blots were developed using 
the iBright imager for chemiluminescence signal and quantified using FIJI software. Membrane 
was stripped and probed with total p70 S6K (CST) to determine total levels of S6K present in the 
samples. The phospho-p70 S6K signal was normalized to the total p70 S6K signal for each 
condition. All samples were then normalized to the no treatment control to determine the fold 
change over baseline for each condition. Five biological replicates were performed. Statistical 




cAMP assays  
PC12 cells stably expressing SpH-KOR (SpH-KOR cells) or CHO cells stably expressing 
Flag epitope tagged human KOR (CHO-KOR cells) cells (10,000/well) were treated with Dyn A, 
Dyn B, Dyn A8, or a-neo (1 mM) for 30 min at 37˚C in HBSS assay buffer containing 10 mM 
HEPES, 20 mM forskolin, and protease inhibitor cocktail (Sigma-Aldrich; Cat. No. P2714) and 
cAMP levels were quantified using the HitHunter cAMP detection kit from DiscoveRx 
according to the manufacturer’s protocol. In a separate set of experiments dose–response curves 
were carried out with Dyn A or Dyn B (0–10 mM). In another set of experiments cells were 
treated Dyn A or Dyn B (1 mM) for 5 min, after which peptides were washed out and cells were 
incubated in assay buffer for 25 min. Cells were then given a second 5 min treatment with Dyn A 
or Dyn B (1 mM) and cAMP levels measured. Values obtained in the absence of peptide were 
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Abstract 
Membrane trafficking and receptor signaling are two fundamental cellular processes that 
interact constantly. Although how trafficking regulates signaling is well studied, how signaling 
pathways regulate trafficking is less well understood. Here we use the mu opioid receptor 
(MOR), the primary target for opioid analgesics, to define a signaling pathway that dynamically 
regulates post-endocytic receptor recycling. By directly visualizing individual MOR recycling 
events, we show that agonist increases MOR recycling. Inhibition of Gβγ, Phospholipase-C, or 
Protein Kinase C mimicked agonist removal, while activation of Gβγ increased recycling even 
after agonist removal. Phosphorylation of serine 363 on the C-terminal tail of MOR was required 
and sufficient for agonist-mediated regulation of MOR recycling. Our results identify a feedback 
loop that regulates MOR recycling via Gβγ, Protein Kinase C, and receptor phosphorylation. 







The dynamic relationship between trafficking and signaling of receptors is currently being 
redefined by new paradigms that are emerging in the field. This is especially true in the case of G 
protein–coupled receptors (GPCRs), the largest class of signaling receptors in humans (Pierce et 
al., 2002; Sriram and Insel, 2018). Activated GPCRs signal via multiple signaling pathways, 
some of which cause receptors to be internalized and trafficked to endosomes. Internalized 
GPCRs may be either recycled back to the surface or degraded. Classically, this endocytic 
trafficking was thought to primarily control the desensitization and resensitization of signaling 
via G proteins by removing receptors from or returning receptors to the cell surface (Lefkowitz 
et al., 1997; Marchese et al., 2008). However, recent evidence shows that many GPCRs can 
signal from intracellular sites, and that intracellular signaling can have distinct downstream 
effects compared with signaling from the surface (Irannejad et al., 2013; Vilardaga et al., 
2014; Thomsen et al., 2018). Intracellular signaling from endosomal microdomains might be a 
general characteristic of GPCRs, as the list of GPCRs that can signal from intracellular 
compartments is still growing (Caengprasath and Hanyaloglu, 2019; Weinberg et al., 2019). This 
supports the emerging idea that an equally important role of trafficking is to transfer receptors 
between distinct signaling environments within a cell. 
In the endosome, receptors need to be localized to specific endosomal microdomains both 
to sort into specific recycling pathways and to signal (Ferrandon et al., 2009; Vistein and 
Puthenveedu, 2013; Bowman et al., 2016). The localization of receptors in these domains and 
their further intracellular sorting are mediated by specific sequences on the C-terminal tails of the 
receptors (Tanowitz and von Zastrow, 2003; Bowman and Puthenveedu, 2015; Bahouth and 
Nooh, 2017). For some of these sequences, interacting proteins that mediate this sorting and 
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recycling have been identified (Romero et al., 2011; Dunn and Ferguson, 2015; Broadbent et al., 
2017). Nevertheless, how this sorting and recycling is dynamically regulated by signaling 
pathways is a fundamental question that is still not well understood. 
The mu opioid receptor (MOR) is an excellent model GPCR that can be used to address 
this question. MOR is highly physiologically relevant, as it is the primary target for many 
currently used and abused opioid drugs. Endosomal sorting of MOR, based on a unique leucine-
based sequence, can dynamically regulate its responses to different agonists at cellular and 
organismal levels (Williams et al., 2013; Bowman et al., 2015; Weinberg et al., 2017) MOR 
undergoes rapid phosphorylation and dephosphorylation in response to agonists, and 
heterologous manipulation of this phosphorylation regulates its plasma membrane localization, 
trafficking, and signaling (Feng et al., 2011; Just et al., 2012; Bowman et al., 2015; Halls et al., 
2016; Arttamangkul et al., 2018). 
In this study, we used a real-time live-cell-imaging assay that resolves MOR recycling at 
single-event resolution to study the homologous signals that allow self-regulation of endosomal 
sorting of MOR. We show that activation of MOR initiates downstream signaling cascades that 
enhance postendocytic receptor recycling back to the cell surface. The signaling cascade requires 
the Gβγ-activated phospholipase C (PLC)/protein kinase C (PKC) signaling pathway, which 
results in the phosphorylation of serine 363 on MOR’s C-terminal tail. This phosphorylation is 
required for increased MOR recycling. The positive feedback loop that regulates MOR endocytic 
trafficking that we describe here may serve as a template for similar adaptive self-regulatory 






The Opioid Agonist DAMGO Increases Post-endocytic Recycling of MOR. 
To determine if the signals downstream of activated MOR regulate its own post-
endocytic recycling, we quantitated MOR recycling using a live cell imaging assay that resolves 
individual MOR recycling events without the confounding effects of endocytosis. To visualize 
recycling events, MOR was N-terminally tagged with a pH-sensitive GFP (SpH) 
(Sankaranarayanan et al., 2000). HEK293 cells stably expressing MOR that was N-terminally 
tagged with the pH-sensitive GFP superecliptic phluorin (SpH-MOR) were imaged using total 
internal reflection fluorescence microscopy. SpH-MOR on the cell surface is fluorescent and 
readily detectable. After activation, receptors are internalized into acidic endosomal 
compartments where the SpH fluorescence is quenched. When recycling vesicles containing 
receptors fuse back to the plasma membrane during an exocytic event, the SpH fluorescence is 
exposed to the neutral pH of the extracellular medium and is therefore dequenched. This 
coordinated dequenching generates a characteristic “puff” of fluorescence that is readily 
detectable (Supplemental Movie 1). We and others have extensively characterized these and 
similar puffs previously and confirmed that they represent individual vesicle fusion events during 
receptor recycling (e.g., Yudowski et al., 2006; Bowman et al., 2015; Logan et al., 2017). 
Individual fusion events were readily observed after cells expressing SpH-MOR were 
treated with the opioid agonist DAMGO for 5 minutes (Figure 3.1A and B). Agonist-containing 
medium was washed out and replaced with medium containing naltrexone. Recycling movies 
were recorded 1 and 6 minutes after this washout (Figure 3.1C) and the number of individual 
events was normalized to the area in each cell. The raw recycling rate per cell area ± washout 
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was determined for each recycling movie (Figure 3.1D). This approach allowed us to follow 
changes in the same cells over time and to normalize the raw values to the baseline recycling rate 
in each condition for each cell (Figure 3.1E). When compared with cells continuously exposed to 
agonist for similar times (Figure 3.1D), the number of MOR recycling events decreases from 
baseline following agonist removal (P < 0.0001). Additionally, the normalized data matched at 
the same time points indicate statistically significant differences in recycling at 1 minute (P < 
0.0001) and 6 minutes (P < 0.0001) for −washout versus +washout (Figure 3.1E). These results 






Figure 3.1. The opioid agonist DAMGO increases postendocytic recycling of MOR. (A) 
HEK293 cell expressing SpH-MOR imaged with total internal reflection fluorescence 
microscopy after DAMGO addition. The appearance of an individual exocytic recycling event is 
denoted by red boxes. Images are 100 ms apart. Scale bar, 5 µm. (B) Profile of an individual 
exocytic event (puff) over 1 s. Frames are 100 ms apart. Scale bar, 1 μm. The event begins as a 
defined spot of fluorescence intensity that appears suddenly. The fluorescence diffuses on the 
cell membrane as shown by the heat map surface plot. (C) Experimental paradigm to study MOR 
postendocytic recycling. (D) The number of recycling events normalized to cell area (square 
micrometer) over time ± DAMGO washout after the baseline recording. In the −washout 
condition, P > 0.999 for baseline versus +1 minute and P = 0.306 for baseline versus +6 minutes 
(n = 15 cells). In the +washout condition, ****P < 0.0001 for both baseline versus 1-minute 
washout and baseline versus 6-minute washout (n = 27 cells). Mean and S.E.M. are plotted for 
each time point. (E) The percentage of recycling events in each condition (±washout) was 
normalized to the baseline events for each condition. ****P < 0.0001 for −washout 1 minute 
versus +washout 1 minute. ****P < 0.0001 for −washout 6 minutes versus +washout 6 minutes 
(−washout: n = 15 cells; +washout: n = 27 cells.) Box and whisker plots are shown with all 
points from each condition. 
 
The Agonist-Mediated Increase in MOR Recycling Rate Requires G Protein Signaling. 
To address which signals downstream of receptor activation are involved in regulating 
postendocytic MOR recycling, we first probed the role of G proteins that couple to MOR by 
using the G protein inhibitor pertussis toxin (PTX). In SpH-MOR cells treated with PTX 14–16 
hours before imaging, DAMGO-induced MOR clustering into endocytic domains was not 
inhibited (Figure 3.2A and B), consistent with previous studies (Halls et al., 2016; (Gondin et al., 
2019)). Fluorescence values normalized to the first frames after DAMGO addition were 
quantified for control and PTX-treated cells as an index of receptor internalization. The decrease 
in fluorescence over the first 5 minutes after DAMGO addition was not different between control 
and PTX-treated cells, suggesting that endocytosis of the receptor was not altered due to PTX 
treatment (Figure 3.2C). When individual recycling events were quantified in the PTX condition, 
however, the baseline recycling rate was decreased compared with control (P = 0.0064), as 
shown in the summary data (Figure 3.2D). The full box plots and statistical comparisons are 
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shown in the corresponding panel of Supplemental Figure 3.2 (Supplemental Figure 3.2B). 
Following agonist washout, the recycling rate was unchanged compared with before washout in 
the PTX condition (Figure 3.2D). The normalized recycling for each baseline condition indicates 
a statistically significant change in the percentage of initial recycling between ±PTX at the time 
point 6 minutes after washout (P = 0.0003). These results show that agonist-mediated increase in 
MOR recycling requires G protein signaling. 
Since Gαi negatively regulates protein kinase A (PKA) through its primary effector 
adenylate cyclase, we next tested whether PKA activity changed MOR recycling. PKA inhibition 
by KT5720, an acute PKA inhibitor, did not change MOR recycling compared with untreated 
cells (Figure 3.2F). Further, neither forskolin, which activates adenylate cyclase, thereby 
increasing cAMP and activating PKA, nor subsequent inhibition of PKA in the same cells 
changed MOR recycling rates (Figure 3.2F). These results suggest that, in our cells, cAMP and 














Figure 3.2. The agonist-mediated increase in MOR recycling requires G protein signaling. 
(A) Representative images of HEK293 cell expressing SpH-MOR imaged with total internal 
reflection fluorescence microscopy before and after DAMGO addition. Cells pretreated with 
PTX 14–16 hours before imaging. Scale bar, 5 µm. (B) Following DAMGO addition, SpH-MOR 
clusters on the cell surface before internalizing in both control (Ctrl) and PTX-treated cells. Scale 
bar, 2.5 µm. (C) Quantification of percentage of normalized fluorescence in control and PTX 
conditions for the first 5 minutes following DAMGO addition. Values are normalized to the first 
frames following DAMGO addition (Ctrl: n = 10 cells; PTX: n = 8 cells). (D) Number of 
recycling events per cell area (square micrometer) over time in response to DAMGO washout ± 
PTX. P = 0.0064 for control baseline versus PTX baseline (Ctrl: n = 10 cells; PTX: n = 8 cells). 
Mean and S.E.M. are plotted for each time point. (E) Percentage of baseline recycling events/min 
at washout 6 minutes for each condition; ***P = 0.0003 for control washout 6 minutes versus 
PTX washout 6 minutes (Ctrl: n = 10 cells; PTX: n = 8 cells). Box and whisker plots are shown 
with all points from each condition. (F) Percentage of baseline recycling events/min in response 
to KT5720 (KT; n = 14 cells), forskolin (Fsk; n = 14 cells), or Fsk + KT (n = 14 cells); treatment 
normalized to initial baseline recycling events (one-sample t test: P = 0.908 for baseline vs. +KT; 
P = 0.9758 for baseline vs. +Fsk; P = 0.7886 for baseline vs. +Fsk+KT). Box and whisker plots 




Gβγ Signaling Is Required and Sufficient to Increase Post-endocytic Recycling of MOR. 
We next tested whether Gβγ activation regulates MOR recycling. To test whether 
Gβγ activation was required, we inhibited Gβγ using gallein, a small-molecule inhibitor of 
Gβγ activation, and measured MOR recycling (Bonacci et al., 2006). In cells incubated with 
gallein 30 minutes prior to imaging, receptor-mediated clustering and endocytosis were not 
altered with gallein treatment (Supplemental Figure 3.1A), but baseline recycling decreased 
compared with that of untreated cells (P = 0.0046) (Figure 3.3A). Agonist washout in gallein-
treated cells did not decrease recycling to the same extent compared with the control (Figure 
3.3B), suggesting that the agonist-mediated increase in MOR recycling requires Gβγ signaling. 
To test whether Gβγ signaling was sufficient to increase MOR recycling, we activated Gβγ in the 
absence of agonist and measured MOR recycling. We used mSIRK, a cell-permeable peptide 
activator of Gβγ, and the compound 12155, a cell-permeable small-molecule activator of 
Gβγ (Goubaeva et al., 2003; Lehmann et al., 2008; Surve et al., 2014), to activate Gβγ. Both 
Gβγ activators increased the rate of MOR recycling at 1 and 6 minutes after washing out 
DAMGO compared with control cells (Figure 3.3C and D). Interestingly, 12155 increased MOR 
recycling to a lesser degree than mSIRK, which may reflect different Gβγ activation mechanisms 
by these two drugs (Bonacci et al., 2006; Surve et al., 2014). Together, these results indicate that 
Gβγ signaling is required and sufficient to enhance MOR recycling back to the cell surface. 
Our results indicating that Gβγ signaling is required and sufficient to enhance MOR recycling 
were also confirmed by measuring surface levels of SpH-MOR at an ensemble level in live cells 
over time. Since SpH is only fluorescent on the cell surface and not when the receptor is in 
endosomes, the fluorescence signal accurately measures surface levels of MOR (Yudowski et al., 
2009; Vistein and Puthenveedu, 2013). After DAMGO addition, there is a significant decrease in 
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fluorescence intensity (∼50%) as predicted due to receptor internalization. This level reaches a 
plateau around 10 minutes, which indicates a steady state between endocytosis and recycling. 
When agonist is removed in a washout, the steady state is shifted by removing the contribution 
of endocytosis. This results in an increase in fluorescence intensity, which allows us to capture 
the contribution of receptor recycling. 
Multiple fields (n > 15) of cells expressing SpH-MOR were selected for each experiment. 
After collecting a 2-minute baseline signal for each field, DAMGO was added, and the 
fluorescence signal was recorded for 15 minutes until the signal plateaued. After 15 minutes, the 
medium containing DAMGO was washed out and replaced with fresh medium containing 
antagonist (naltrexone) and ±mSIRK or ±12155. The recovery of fluorescence signal was 
measured for 15 minutes after washout to determine a measurement of ensemble MOR recycling 
across cells (Figure 3.3E). In the Gβγ-activating conditions, we observed an initial spike in 
fluorescence signal consistent with the increase we observed in the orthogonal puffs assay 
(Figure 3.3F and G). Overall the increase in fluorescence signal indicates an increase in the 
number of receptors recycled back to the cell surface in response to sustained Gβγ activation 
(Figure 3.3H). These results strongly support that Gβγ signaling is required and sufficient to 












Figure 3.3. Gβγ activation is required and sufficient to increase MOR recycling. (A) 
Number of MOR recycling events per cell area (square micrometer) over time in response to a 
DAMGO washout in control (Ctrl) and gallein conditions. Cells were treated with gallein 30 
minutes prior to imaging. P = 0.0046 for control baseline versus gallein baseline (Ctrl: n = 9 
cells; gallein: n = 25 cells). Mean and S.E.M. are plotted for each time point. (B) Percentage of 
baseline recycling events/min at washout 6 minutes for each condition: P = 0.0015 for control 
washout 6 minutes versus gallein washout 6 minutes (Ctrl: n = 9 cells; gallein: n = 25 cells). Box 
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and whisker plots are shown with all points from each condition. (C) Number of MOR recycling 
events per cell area (square micrometer) over time in response to a DAMGO washout in control, 
mSIRK, and 12155 conditions. Cells were treated acutely with mSIRK or 12155 during the 
washout. Mean and S.E.M. are plotted for each time point (Ctrl: n = 10 cells; mSIRK: n = 12 
cells; 12155: n = 12 cells). (D) Percentage of baseline recycling events/min at washout 1 minute 
for each condition: ***P = 0.0003 for control washout 1 minute versus mSIRK washout 1 
minute; *P = 0.0488 for control washout 1 minute versus 12155 washout 1 minute (Ctrl: n = 10 
cells; mSIRK: n = 12 cells; 12155: n = 12 cells). Box and whisker plots are shown with all points 
from each condition. (E) Changes in surface MOR fluorescence over time measured after 
DAMGO addition and washout. MOR fluorescence decreased upon receptor internalization after 
DAMGO addition and returned upon recycling after DAMGO washout. Gβγ activation by either 
mSIRK or 12155 increased the rate of recovery of fluorescence. Scale bar, 10 μm. (F) 
Quantification of fluorescence recovery over 30 minutes following DAMGO treatment 
normalized to the baseline fluorescence. (G) Quantification of fluorescence recovery normalized 
to the fluorescence loss before washout for control, mSIRK, or 12155 conditions. (H) Box and 
whisker plots showing the fluorescence after 15 minutes of agonist washout in control, mSIRK, 
or 12155 conditions. Gβγ activation by either mSIRK or 12155 increased the receptors recycled; 
****P < 0.0001 for control versus mSIRK, **P = 0.0058 for control versus 12155 (Ctrl: n = 48 
fields; mSIRK: n = 44 fields; 12155: n = 38 fields, all across three independent experiments). 
 
MOR Regulates Its Own Recycling via Phospholipase C, Protein Kinase C, and Serine 363. 
To determine the signals downstream of Gβγ activation that regulated MOR recycling, 
we first examined the role of PLC, which is activated by Gβγ. To test whether PLC inhibition 
changed DAMGO-mediated regulation of MOR recycling, we acutely inhibited PLC with 
U73122 and measured the change in MOR recycling from baseline recycling before PLC 
inhibition. U73122 decreased MOR recycling even in the presence of DAMGO, whereas 
U73343, an inactive control, did not change MOR recycling compared with baseline (Figure 
3.4A). These results suggest that PLC activation is required for the DAMGO-mediated increase 
in MOR recycling. We next tested whether PKC signaling was required to increase MOR 
recycling in the presence of DAMGO. To do this, we acutely inhibited PKC by treating cells 
with chelerythrine or Gö6983 and measured the change in MOR recycling from baseline 
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recycling before PKC inhibition (Figure 3.4B). MOR recycling was reduced when PKC was 
inhibited, suggesting that PKC increased MOR recycling. 
Because the C-terminal tail of MOR contains predicted PKC phosphorylation sites (Doll 
et al., 2011), we tested whether the receptor itself was a target of DAMGO-mediated regulation 
of MOR recycling. Specifically, we focused on serine 363, a putative PKC phosphorylation site, 
as a potential regulator of PKC signaling. To test whether serine 363 was required for DAMGO-
mediated homologous regulation of MOR recycling, we mutated serine 363 on MOR to alanine. 
Receptor-mediated clustering and endocytosis were not different between S363A and wild-type 
(WT) MOR (Supplemental Figure 3.1B). In cells expressing this mutant construct (S363A), 
however, the number of recycling events was decreased compared with the cells expressing the 
wild-type MOR (Figure 3.4C). The reduction in recycling seen upon washout of drug was 
smaller for S363A compared with the wild-type MOR but was not fully abolished, suggesting 
that other residues or mechanisms may be involved in the regulation of DAMGO-mediated 
recycling (Figure 3.4D). Further, the recycling of S363A was also insensitive to Gβγ inhibition 
by gallein (Figure 3.4C and D) Together, these data indicate that phosphorylation at serine 363 is 
required to increase MOR recycling after activation. 
To test if phosphorylation at serine 363 was sufficient to increase MOR recycling in the 
absence of MOR activation, we examined recycling in cells expressing a phosphomimetic MOR 
mutant where serine 363 was mutated to an aspartate (S363D). Baseline recycling was not 
different between the WT MOR and the S363D mutant. However, unlike WT MOR, recycling of 
the S363D mutant did not decrease from baseline after agonist washout (Figure 3.4C), 
suggesting that the phosphomimetic mutation was sufficient to keep MOR recycling at a high 
level even after agonist washout. Together, our results suggest a model of homologous regulation 
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of MOR recycling, where MOR activation phosphorylates the receptor at serine 363 via 




























Figure 3.4. Homologous regulation of MOR recycling by MOR phosphorylation at serine 
363. (A) Percentage of baseline recycling events/min in response to U73122 (n = 17 cells) or 
U73343 (n = 21 cells) treatment normalized to initial baseline recycling events. One-sample t 
test: ***P = 0.0002 for baseline versus U73122; P = 0.8910 for baseline versus U73343. Box 
and whisker plots are shown with all points from each condition. (B) Percentage of baseline 
recycling events/min in response to chelerythrine (n = 20 cells) or Gö6983 (n = 21 cells) 
treatment normalized to initial baseline recycling events. One-sample t test: ***P = 0.0007 for 
baseline versus chelerythrine; ****P < 0.0001 for baseline versus Gö6983. Box and whisker 
plots are shown with all points from each condition. (C) Number of recycling events per cell area 
(square micrometer) over time in response to DAMGO washout in control (Ctrl), S363A, S363A 
+ gallein, or S363D conditions. P = 0.0392 for control baseline vs. S363A baseline; P = 0.0429 
for control baseline vs. S363A + gallein baseline; P = 0.7203 for control baseline vs. S363D 
baseline; P = 0.9391 for S363D baseline vs. S363D washout 6 minutes (Ctrl: n = 18 cells; 
S363A: n = 15 cells; S363A + gallein: n = 19 cells; S363D: n = 10 cells). Mean and S.E.M. are 
plotted for each time point. (D) Percentage of baseline recycling events/min at washout 6 minute 
for each condition: ***P = 0.0003 for control washout 6 minute versus S363A washout 6 
minutes; **P = 0.0077 for control washout 6 minutes versus S363A + gallein washout 6 
minutes; ****P < 0.0001 for control washout 6 minutes versus S363D washout 6 minutes (Ctrl: 
n = 18 cells; S363A: n = 15 cells; S363A + gallein: n = 19 cells; S363D: n = 10 cells). Box and 
whisker plots are shown with all points from each condition. (E) Proposed model of self-































Supplemental Figure 3.1 
 
 
Supplemental Figure 3.1 Clustering and Internalization of MOR across conditions (A) 9.04 
µm x 9.04 µm ROI of HEK293 cell expressing SpH MOR in TIRF +/- gallein and +/- DAMGO 
addition. SpH-MOR clusters on the cell surface in response to DAMGO before internalizing in 
both control and gallein treated cells. Right panel: Quantification of % normalized fluorescence 
in control and gallein conditions for the first 5 minutes following DAMGO addition. Values are 
 
 73 
normalized to the first frame following DAMGO addition. n=15 cells for Ctrl; n=15 cells for 
gallein. (B) 9.04 µm x 9.04 µm ROI of HEK293 cell expressing SpH MOR WT or S363A in 
TIRF +/- DAMGO addition. SpH-MOR clusters on the cell surface in response to DAMGO 
before internalizing in both control and S363A conditions. Right panel: Quantification of % 
normalized fluorescence in control and S363A conditions for the first 5 minutes following 
DAMGO addition. Values are normalized to the first frame following DAMGO addition. n=6 
cells for Ctrl; n=15 cells for S363A. (C) 9.04 µm x 9.04 µm ROI of HEK293 cell expressing 
SpH MOR WT or S363A(treated with gallein) in TIRF +/- DAMGO addition. SpH-MOR 
clusters on the cell surface in response to DAMGO before internalizing in both control and 
S363A + gallein conditions. Right panel: Quantification of % normalized fluorescence in control 
and S363A + gallein conditions for the first 5 minutes following DAMGO addition. Values are 
normalized to the first frame following DAMGO addition. n=6 cells for Ctrl; n=10 cells for 
S363A + gallein. (D)9.04 µm x 9.04 µm ROI of HEK293 cell expressing SpH MOR WT or 
S363D +/- DAMGO addition. SpH-MOR clusters on the cell surface in response to DAMGO 
before internalizing in both control and S363D conditions. Right panel: Quantification of % 
normalized fluorescence in control and S363D conditions for the first 5 minutes following 
DAMGO addition. Values are normalized to the first frame following DAMGO addition. n=5 








Supplemental Figure 3.2. Raw MOR recycling events across all conditions. 
“*” denotes statistical significance (p<0.05) within family (condition) in Two-Way ANOVA.  
“#” denotes statistical significance (p<0.05) between families at the same time points. 
(A)  Number of recycling events per cell area (μm2) over time in response to DAMGO in +/-
Washout conditions. p>0.9999 for - Washout baseline vs. - Washout 1 min; p=0.3063 for - 
Washout baseline vs. - Washout 6 min. p<0.0001 for + Washout baseline vs. + Washout 1 min; 
p<0.0001 for + Washout baseline vs. + Washout 6 min. Unpaired t test: p=0.2854 for - Washout 
baseline vs. + Washout baseline; p=0.0042 for - Washout 1 min vs. + Washout 1 min; p<0.0001 
for - Washout 6 min vs. + Washout 6 min; - Washout: n=15 cells; + Washout: n=27 cells 
(B)  Number of recycling events per cell area (μm2) over time in response to DAMGO washout 
in control or PTX conditions. p =0.0090 for Ctrl baseline vs. Ctrl 1 min; p<0.0001 for Ctrl 
baseline vs. Ctrl 6 min. p=0.8650 for PTX baseline vs. PTX 1 min; p=0.6789 for PTX baseline 
vs. PTX 6 min. Unpaired t test: p=0.0064 for Ctrl baseline vs. PTX baseline; p=0.0127 for Ctrl 1 
min vs. PTX 1 min; p=0.3216 for Ctrl 6 min vs. PTX 6 min. Ctrl: n=10 cells; PTX: n=8 cells 
(C)  Number of recycling events per cell area (μm2) over time in response to DAMGO washout 
in control or gallein conditions. p<0.0001 for Ctrl baseline vs. Ctrl 1 min; p<0.0001 for Ctrl 
baseline vs. Ctrl 6 min; p=0.1561 for gallein baseline vs. gallein 1 min; p=0.0018 for gallein 
baseline vs. gallein 6 min. Unpaired t test: p=0.0046 for Ctrl baseline vs. gallein baseline; 
p=0.0778 for Ctrl 1 min vs. gallein 1 min; p=0.2675 for Ctrl 6 min vs. gallein 6 min. Ctrl: n=9 
cells; Gallein n=25 cells (D)  Number of recycling events per cell area (μm2) over time in 
response to DAMGO washout in control, mSIRK, or 12155 conditions. p=0.0083 for Ctrl 
baseline vs. Ctrl 1 min; p=0.0002 for Ctrl baseline vs. Ctrl 6 min; p=0.0026 for mSIRK baseline 
vs. mSIRK 1 min; p=0.3378 for mSIRK baseline vs. mSIRK 6 min; p=0.7501 for 12155 baseline 
vs. 12155 1 min; p=0.9174 for 12155 baseline vs. 12155 6 min. Sidak’s multiple comparisons 
test: p=0.8845 for Ctrl baseline vs. mSIRK baseline; p=0.8397 for Ctrl baseline vs. 12155 
baseline; p=0.0005 for Ctrl 1 min vs. mSIRK 1 min; p=0.2760 for Ctrl 1 min vs. 12155 1 min; 
p=0.0021 for Ctrl 6 min vs. mSIRK 6 min; p=0.1079 for Ctrl 6 min vs. 12155 6 min. Ctrl: n=10 
cells; mSIRK: n=12 cells; 12155: n=12 cells (E)  Number of recycling events per cell area (μm2) 
over time in response to DAMGO washout in control, S363A, S363A + gallein, or S363D 
conditions. p<0.0001 for Ctrl baseline vs. Ctrl 1 min; p<0.0001 for Ctrl baseline vs. Ctrl 6 min; 
p=0.9682 for S363A baseline vs. S363A 1 min; p=0.0047 for S363A baseline vs. S363A 6 min; 
p=0.1553 for S363A + gallein baseline vs. S363A + gallein 1 min; p=0.0093 for S363A + gallein 
baseline vs. S363A + gallein 6 min; p=0.9539 for S363D baseline vs. S363D 1 min; p=0.9391 
for S363D baseline vs. S363D 6 min; Sidak’s multiple comparisons test: p=0.0392 for Ctrl 
baseline vs. S363A baseline; p=0.0429 for Ctrl baseline vs. S363A + gallein baseline; p=0.7023 
for Ctrl baseline vs. S363D baseline; p=0.8718 for Ctrl 1 min vs. S363A 1 min; p=0.5442 for 
Ctrl 1 min vs. S363A + gallein 1 min; p=0.0370 for Ctrl 1 min vs. S363D; p=0.9752 for Ctrl 6 
min vs. S363A 6 min; p=0.9990 for Ctrl 6 min vs. S363A + gallein 6 min; p<0.0001 for Ctrl 6 
min vs. S363D 6 min. Ctrl: n=18 cells; S363A: n=15 cells; S363A + gallein: n=9 cells; S363D: 









We identify a positive feedback mechanism that mediates homologous regulation of MOR 
recycling. Activation of MOR initiates a signaling cascade via Gβγ and PKC that increases the 
rate of MOR recycling. This increase in recycling requires the phosphorylation of MOR at serine 
363, a site that can be directly phosphorylated by PKC. 
Our results provide new information on how receptor phosphorylation can regulate MOR 
trafficking. Phosphorylation of MOR, mainly at the TSST (residues 354–357) and the STANT 
(residues 375–379) motifs, by multiple kinases, has been studied extensively for its role in 
receptor internalization and desensitization (Williams et al., 2013; Arttamangkul et al., 
2018; Miess et al., 2018; Kliewer et al., 2019). PKC can phosphorylate MOR at multiple sites, 
but the residues that are phosphorylated in vivo and the role of PKC phosphorylation in 
regulating MOR trafficking and function are still being investigated (Doll et al., 2011; Feng et 
al., 2011; Yousuf et al., 2015). The serine 363 residue that we identified as critical for regulating 
MOR recycling can be phosphorylated in vitro by PKCε, although whether this is the primary 
enzyme that phosphorylates it in vivo is not clear (Doll et al., 2011; Feng et al., 2011). PKC 
activation by MOR on the plasma membrane varies between different agonists used (Halls et al., 
2016). Further, activation of PKC downstream of Gβγ can regulate receptor localization to 
different domains on the plasma membrane (Halls et al., 2016). Once internalized, the 
phosphorylation of MOR at specific residues can determine receptor sorting between Rab4- and 
Rab11-dependent recycling compartments (Wang et al., 2008). In this context, the rate and 
extent of dynamic changes in phosphorylation at S363 of MOR is not clear. In biochemical 
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assays, the bulk levels of S363 phosphorylation do not change after agonist treatment (Lau et al., 
2011; Moulédous et al., 2015). Considering our data, that this site is required and sufficient to 
mediate agonist-mediated increase in MOR recycling, it is possible that phosphorylation at this 
site is locally and transiently regulated in response to receptor activation. 
Regulation of MOR recycling by Gβγ-, PLC-, and PKC-mediated receptor phosphorylation 
is a novel example of homologous regulation of GPCR recycling. Receptor phosphorylation has 
been studied mainly in the context of receptor desensitization and endocytosis, but 
phosphorylation can regulate the recycling of other receptors such as the β adrenergic receptors. 
In the case of the β2-adrenoreceptor (β2AR), a prototypical Gαs-coupled receptor, receptor 
recycling is regulated by receptor phosphorylation downstream of receptor signaling. However, 
unlike for MOR, agonist stimulation decreased the postendocytic recycling of β2AR. This 
decrease required PKA-mediated phosphorylation of β2AR on serine 345/346 (Yudowski et al., 
2009; Vistein and Puthenveedu, 2013). PKA signaling, however, does not play a role in MOR 
recycling in our cells (Fig. 2F). MOR recycling in striatal neurons has been reported to be 
inhibited by forskolin, although PKA was not directly tested (Roman-Vendrell et al., 2012). This 
difference could reflect differences in mechanisms of recycling of β2AR and MOR, which might 
also differ between cell types. In HEK cells, β2AR recycles via a specialized set of endosomal 
tubules, termed ASRT tubules, characterized by the presence of an actin-SNX-retromer complex 
(Puthenveedu et al., 2010; Temkin et al., 2011). β2AR sorting into these tubules requires the 
interaction of a C-terminal post-synaptic density-95/disc large tumor suppressor/zonula 
occludens-1 (PDZ) ligand sequence with a set of PDZ-containing proteins, which ultimately link 
the receptor to the endosomal actin cytoskeleton (Temkin et al., 2011). MOR seems to recycle 
via a distinct mechanism, although the mechanism itself is not understood. MOR recycling 
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requires a unique “bileucine” sequence on the receptor C-terminal tail. There is no evidence that 
this sequence interacts with the PDZ-containing proteins or actin. Further, β2AR and MOR 
might also use different sets of Rab proteins to recycle (Wang et al., 2008). The use of both Gα- 
and Gβγ-mediated pathways to phosphorylate receptor cargo via distinct kinases to regulate 
recycling of receptors through potentially distinct pathways suggests that homologous regulation 
of receptor recycling by modifying receptor phosphorylation states is a conserved mechanism on 
a global level, although the specific mechanisms might vary between different GPCRs. 
The changes we observe in MOR recycling based on PKC-mediated receptor 
phosphorylation could have direct effects on MOR signaling and function. Many canonical 
GPCRs have been shown to signal from endosomes in the recent past, raising the idea that 
endosomal signaling is the norm rather than the exception (Calebiro et al., 2009; Vilardaga et al., 
2014; Bowman et al., 2016; Jensen et al., 2017; Eichel and von Zastrow, 2018). When localized 
to specific microdomains on the endosome, β2AR activates the transcription of a complement of 
genes that are distinct from those activated by signaling from the plasma membrane (Tsvetanova 
and von Zastrow, 2014; Bowman et al., 2016). Endosomal signaling of the neurokinin-1 receptor 
in spinal neurons, or the calcitonin gene-related peptide-targeted calcitonin-like receptor, 
contributes to nociception (Jensen et al., 2017; Yarwood et al., 2017; Weinberg et al., 2019). 
Whether MOR signaling from endosomes has a distinct signaling consequence is less clear. 
However, increased recycling of MOR, induced by neurokinin-1 receptor signaling, can decrease 
acute tolerance to opioids, suggesting that the rate of recycling can regulate opioid physiology 
(Bowman et al., 2015). PKC-mediated phosphorylation of MOR could therefore serve as a 
convergence point for both homologous regulation of MOR recycling by Gβγ and heterologous 
regulation by other signaling pathways. Importantly, considering emerging data that the precise 
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location of receptors could dictate PKC-mediated phosphorylation of MOR, this could regulate 
both the rate of resensitization as well as the spatial encoding of opioid signaling, which has 
emerged as an exciting area of study in the recent past (Sorkin and von Zastrow, 
2009; Tsvetanova and von Zastrow, 2014; Bowman et al., 2016; Eichel and von Zastrow, 2018). 
Similar feedback loops may serve as templates for adaptive self-regulation of signaling for many 
GPCRs, although the specific mechanisms may vary between different receptors. Understanding 
the regulation of GPCR trafficking, using assays that can directly detect and measure these 
dynamic events in real time, will allow us to better analyze the relationship between receptor 
trafficking and the spatiotemporal aspects of GPCR signaling. 
 
3.4 Materials and Methods 
Reagents, Constructs, and Cells. 
[D-Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO; used at 10 µM), naltrexone (10 µM), 
pertussis toxin (100 ng/ml, overnight treatment), forskolin (10 µM), KT5720 (1 µM), myr-
SIRKALNILGYPDYD-OH (mSIRK; 10 µM), U73122 (10 µM), and chelerythrine (5 µM) were 
purchased from Sigma-Aldrich (St. Louis, MO). Gallein (20 µM, 30 minute treatment), U73343 
(10 µM), and Gö6983 (5 µM) were purchased from Tocris Bioscience. Compound 12155 
(10 µM) was provided by Dr. Alan Smrcka (University of Michigan). Stable nonclonal HEK293 
cells (American Type Culture Collection CRL-1573) expressing superecliptic phluorin (SpH)-
MOR were selected in Geneticin (Invitrogen) and grown in Dulbecco’s modified Eagle’s 
medium (Hyclone) + 10% fetal bovine serum (Gibco). The SpH-MOR-S363A point mutant 
thereof has been described previously (Soohoo and Puthenveedu, 2013; Bowman et al., 2015). 
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SpH-MOR-S363D was generated by Q5 Site-Directed Mutagenesis Kit (New England Biolabs) 
using ACAGCAAAACGATGCTCGAATCCG as the forward primer and TCGATTGTGGAG
GAAGTTG as the reverse primer. 
Live Cell Imaging. 
Cells were passed to 25-mm glass coverslips coated with poly-D-lysine and imaged 2 
days later. Cells were imaged live in Leibovitz L15 imaging medium (Gibco) and 1% fetal 
bovine serum at 37°C in a temperature- and CO2-controlled chamber. A Nikon Eclipse Ti 
automated inverted microscope with a 60×/1.49 N.A. total internal reflection fluorescence 
objective and confocal 20×/0.75 N.A. objective was used for imaging. Images were acquired 
with an iXon+ 897 electron-multiplying charge-coupled device camera (Andor, Belfast, UK) 
with a solid-state laser of 488 nm as a light source. Images were scrambled using a scrambler.py 
script (https://gist.github.com/SavinaRoja/1629319) before analyzing them in FIJI (National 
Institutes of Health) (Schindelin et al., 2012). 
Quantification of Individual Recycling Events. 
HEK293 cells stably expressing SpH-MOR or its mutants were treated with DAMGO for 
5 minutes to induce receptor clustering and internalization at 37°C. Receptor clustering was 
visualized by acquiring an image every 3 seconds for 5 minutes. A baseline recycling movie was 
acquired at 10 Hz for 1 minute using total internal reflection fluorescence microscopy, followed 
by a washout with antagonist (naltrexone). Subsequent movies were collected 1 and 6 minutes 
after washout. The number of individual exocytic recycling events in each movie was manually 
scored. The box plots display the median and the entire range with outliers excluded. To evaluate 
the effect of agonist washout on the frequency of recycling events between treatment conditions, 
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two-way repeated-measures ANOVAs were conducted on the raw recycling rates followed by 
post hoc comparisons of means within the treatment condition to the baseline recycling rate. 
These tests were conducted separately for each of the sets of conditions shown in Figs. 
1D; 2D; 3, A and C; and 4C. Supplemental Figure 2. To compare the magnitude of the washout 
effect between treatment conditions, recycling events for each cell were normalized to that cell’s 
recycling rate in the baseline movie. The mean normalized recycling rate was then compared 
between conditions of interest using either a one-way ANOVA followed by the indicated post 
hoc comparisons using Dunnett’s multiple comparisons correction (Figures 3.1E, 3.3D, and 
3.4D) or a single paired Student’s t test when only two conditions were evaluated (Figures 3.2E 
and 3.3B). When testing whether a pharmacological treatment was able to perturb the basal rate 
of recycling, the normalized recycling events were compared with a theoretical mean of 100% 
using a single-sample Student’s t test (Figures 3.2F, 3.3A and B).  
Ensemble Recycling Assay. 
To measure ensemble recycling, receptor surface levels were imaged using confocal 
microscopy with a 20× objective and 488-nm laser. Images were collected at 30-second intervals 
for 20 different fields. Baseline recordings for 2 minutes (four frames) were collected before the 
addition of DAMGO. After the addition of agonist, images were collected for 15 minutes. After 
15 minutes, agonist was removed. The cells were rinsed with fresh imaging medium, and 
antagonist (naltrexone) was added to the new medium. After agonist washout, images were 
collected for another 15 minutes. Fluorescence intensities were corrected by a background 
threshold and normalized by the average fluorescence of the baseline four frames collected 
before DAMGO treatment. Surface fluorescence analysis was conducted using an ImageJ Macro 
automated script (National Institutes of Health) (https://zenodo.org/record/2645754). 
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Fluorescence recovery/loss ratios after washout were quantified by normalizing the fluorescence 
values after washout to the total fluorescence lost before washout. Cell fields that did not respond 
to DAMGO treatment were excluded from analysis. Statistical significance was determined by 
using a one-way ANOVA comparing endpoints of all conditions to the control condition, 
followed by post hoc comparisons between all means (Figure 3.3H).  
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Chapter 4: Regulation of Mu Opioid Receptor Trafficking and 




   
Dynamic phosphorylation of the mu opioid receptor (MOR) is an important regulatory 
mechanism for receptor trafficking and signaling. Specifically phosphorylation sites on the c-
terminal tail have been implicated in changing receptor sorting in response to agonist activation. 
Here we investigate how two key phosphorylation sites serine363 (S363) and threonine370 




Post-translational modifications of G protein-coupled receptors (GPCRs) are key 
determinants for receptor function. Agonist-dependent phosphorylation of the C-terminus is one 
major regulatory post-translational modification. The physiologically relevant, mu opioid 
receptor (MOR) contains several phosphorylation sites in the C-terminal cytoplasmic tail located 
in the conserved 370TREHPSTANT379 sequence (Mann et al., 2015). Previous work from our lab 
suggests hierarchical sorting of MOR based on its phosphorylation state. As mentioned 
previously, phosphorylation at S363 regulates recycling back to the cell surface in an initial Gβγ-
dependent mechanism (Kunselman et al., 2019). As another example of phosphoregulatory 
sorting, T370A receptors sort primarily into actin-positive domains, suggesting a role for C-
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terminal tail phosphorylation in receptor endosomal distribution (Bowman, 2016). In light 
of previous work highlighted above with the kappa opioid receptor (KOR) and for the B2AR 
intracellular signaling (Kunselman et al., 2021; Bowman et al., 2016), we wanted to test the role 
phosphorylation had in regulating MOR signaling profiles and its activity in endosomes.  
4.2 Results 
To assess the role of phosphorylation at sites S363 and T370 on MOR recycling, we tested 
recycling in three stable HEK293 cell lines that express either wildtype (WT), S363A, and 
T370A SpH-MOR, which have been previously reported in Kunselman et al., 2019 and Bowman 
et al., 2015. We imaged cells using TIR-FM. After 5 min of DAMGO treatment, we 
photobleached the cell surface and recorded movies for 1 min at 10Hz. The number of exocytic 
events were recorded for each condition and normalized by cell area to determine the initial 
recycling rate. The initial rates of recycling were not statistically different between WT and 
T370A recycling, while S363A had decreased recycling (Figure 4.1A). Additionally, cells 
expressing the T370A receptor showed decreased recycling when treated with a Gβγ inhibitor, 
gallein, (Figure 4.1B) similarly to the WT receptor, while S363A showed gallein insensitivity as 














Figure 4.1  
 
 
Figure 4.1. Recycling rates for wildtype MOR and phosphodeficient mutants S363A and 
T370A in HEK293 cells. 
(A) HEK293 cells stably expressing WT, S363A, or T370A SpH-MOR. Number of recycling 
events per cell area (square micrometer) over time in response to 5 min DAMGO treatment. 
(B) Number of recycling events per cell area (square micrometer) over time in response to 5 
min DAMGO treatment in cells expressing T370A SpH-MOR treated with or without 30 min 
Gallein pretreatment.   
 
 
Next we wanted to test if these phosphodeficient mutants were capable of signaling from 
intracellular compartments. To do this we used three stable HEK293 cells expressing either WT, 
S363A, or T370A FLAG-MOR. We transfected Nb39-YFP, a nanobody that recognizes that 
active conformation into each cell line to examine if MOR was in the activate conformation after 
DAMGO treatment. After 20 minutes of DAMGO, Nb39 colocalizes to endosomal receptor in 
all three conditions (Figure 4.2A). To quantify colocalization, we scored the total number of 
MOR positive endosomes using an Image J macro “Object Picker” to determine the percent 









Figure 4.2. Endosomal recruitment of active conformation biosensor (Nb39) for wildtype 
MOR and phosphodeficient mutants S363A and T370A in HEK293 cells. 
(A)  HEK293 cells stably expressing WT, S363A, or T370A FLAG-MOR transfected with 
Nb39-YFP. Representative images show endosomal FLAG-MOR colocalized with Nb39 after 
20 min DAMGO treatment. (B) The percent colocalization of Nb39 with total MOR endosomes 
is quantified for each WT, S363A, and T370A expressing cells.  
 
 
We next wanted to test if the phospho-deficient mutants had altered extracellular signal-
regulated kinases (ERK) signaling, based on previous data, which shows that different opioid 
ligands and the bileucine receptor sequence regulate lifetimes at the cell surface and ERK 
signaling (Weinberg et al., 2017). To do this we used three stable HEK293 cells expressing 
either WT, S363A, or T370A FLAG-MOR. We treated cells with +/- DAMGO for 5 minutes and 
then blotted for phosphoERK and total ERK to measure activation of ERK signaling. The S363A 
mutant showed increased phosphoERK in comparison to the T370A mutant and WT receptor 










Figure 4.3. Phosphorylated ERK after activation of wildtype MOR and phosphodeficient 
mutants S363A and T370A in HEK293 cells.  
(A) HEK293 cells stably expressing WT, S363A, or T370A FLAG-MOR were treated with 5 
min DAMGO and phosphoERK (pERK) levels were probed in an immunoblot. The membrane 
was stripped and reprobed with totalERK (tERK). (B) Fold change over baseline was calculated 
for each receptor condition by normalizing the pERK signal over the tERK signal for DAMGO 
treated conditions to the untreated conditions.  
 
4.3 Discussion 
These experiments suggest that there are some key differences in trafficking and signaling 
between the phosphorylation mutants. The S363A mutant shows decreased initial recycling and 
increased ERK signaling, while the T370A mutant is more similar to the wildtype receptor in 
readouts for recycling and ERK signaling. Wildtype MOR, S363A, and T370A all show similar 
levels of Nb39 recruitment to endosomal compartments after 20 minutes of DAMGO treatment. 
However, there may be differences detected under other conditions, such as different cell-types  
or changes in the signaling environment. Interestingly, T370A receptors appear to sort primarily 
into actin-positive domains, which further suggests that phosphorylation may regulate 
hierarchical receptor sorting (Bowman, 2016). 
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Another interesting question to address is the stage at which receptor phosphorylation is 
occurring during endocytosis and whether that correlates with distinct sorting throughout the 
endolysosomal pathway. Previous studies that used phospho-antibodies developed to recognize 
these specific sites showed that S363 is constitutively phosphorylated, while T370 
phosphorylation is dependent on the agonist (Doll et al., 2011). However, phosphorylation at 
S363 does occur in a homologous mechanism regulated by DAMGO activation (Kunselman et 
al., 2019), suggesting that these sites could be dynamically regulated at different points after 
receptor activation and at steady-state. The kinases involved in phosphorylation may also change 
depending on the cell-type. For example, previous evidence suggests that T370 is phosphorylated 
by GRK 2/3 in addition to PKC (Mann et al., 2015).  
 Taken together these findings support additional layers of regulation through changes in 
MOR phosphorylation. The combination of homologous and heterologous signaling resulting in 
distinct spatial and temporal phosphorylation may be a mechanism of cellular resensitization in 
response to numerous external stimuli.   
 
4.4 Materials and Methods 
 
Live Cell Imaging 
  
Cells were imaged using a Nikon TE-2000E inverted microscope with a 60X 1.49 NA 
TIRF objective, Andor Revolution XD spinning disk confocal system, and 488 and 647 nm 
solid-state lasers. Cells were imaged in Leibowitz’s L15 medium (Gibco), 1% FBS, at 37˚C. 
Images were acquired using an Andor iXon+ EM-CCD camera using Andor IQ.  
Quantification of Individual Recycling Events. 
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HEK293 cells stably expressing SpH-MOR or its mutants were treated with DAMGO for 
5 minutes to induce receptor clustering and internalization at 37°C. Receptor clustering was 
visualized by acquiring an image every 3 seconds for 5 minutes. A baseline recycling movie was 
acquired at 10 Hz for 1 minute using total internal reflection fluorescence microscopy, followed 
by a washout with antagonist (naltrexone). Subsequent movies were collected 1 and 6 minutes 
after washout. The number of individual exocytic recycling events in each movie was manually 




HEK293 cells stably expressing FLAG-MOR (WT, S363A, or T370A) were grown in a 
PDL coated 12-well plate for 2 days at 37˚C. Cells were for four hours in serum-free media and 
then treated with 10 µM DAMGO for 5 min. Cells were placed on ice and rinsed twice with PBS 
containing calcium and magnesium. Cells were directly lysed in the plate using 2 RSB (Bio-Rad, 
Hercules, CA). Lysates were placed on ice for 5 min and then placed at 95˚C for 5 min. Lysates 
were run on 10% stain-free gels (BioRad), which were then transferred to nitrocellulose 
membrane overnight. Membranes were blocked in 5% BSA and then probed with 
phosphoERK(CST) to detect phosphorylated ERK 1/2 levels in each condition. Blots were 
developed using the iBright imager for chemiluminescence signal and quantified using FIJI 
software. Membrane was stripped and probed with total ERK 1/2 (CST) to determine total levels 
of ERK 1/2 present in the samples. The phospho-ERK signal was normalized to the total ERK 
signal for each condition. All samples were then normalized to the no treatment control to 
determine the fold change over baseline for each condition. Five biological replicates were 
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Chapter 5: Conclusions and Future Directions 
 
Together, the data presented in this thesis highlight the mechanisms regulating G protein-
coupled receptor (GPCR) function via modulation of receptor trafficking and signaling. 
Specifically, I investigated the mechanisms underlying differential opioid receptor activity in 
response to endogenous opioid peptide ligands. In chapter one, I reviewed regulators of GPCR 
endocytic trafficking and biosynthetic trafficking, which showcased various points of regulation 
from lipid membrane composition to post-translational modifications of the receptor itself. 
Additionally, agonist-dependent sorting is an area of particular interest in this dissertation. 
In chapter two, I examined kappa opioid receptor (KOR) trafficking and signaling in 
response to different, yet highly-related, dynorphin peptides. Interestingly, we observed that 
dynorphin A localizes KOR to lysosomes and drives degradation, while dynorphin B localizes 
KOR into recycling endosomes and drives recycling. Strikingly, KOR activated by dynorphin 
A, but not dynorphin B, remains in an active conformation on lysosomes and causes sustained 
cAMP signaling. This study shows that different endogenous opioid peptides fine-tune KOR 
signaling by regulating receptor localization to and signaling from different endosomal 
compartments.  
Currently, I am investigating changes in gene expression in the context of spatial signaling 
in response to different dynorphin treatments. Additionally, changes in the phosphoproteome in 
response to different agonists may provide insight for functional differences in signaling 
profiles between peptides. Since many of these peptides are thought to be released from the 
same vesicles, I am also interested in testing combinatorial effects of several co-released 
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peptides on receptor trafficking and signaling. Overall this work suggests that physiological 
systems generate diversity in signaling by inducing different subcellular spatial and temporal 
profiles of receptors, which should be an important consideration in drug development. 
In chapter three, I investigated the relationship between receptor signaling and trafficking 
by examining mu opioid receptor (MOR) recycling. My findings show that DAMGO-activated 
MOR initiated downstream signaling via a Gβγ, PLC, and PKC pathway, resulting in the 
phosphorylation of serine 363, which increased MOR recycling. Interestingly, this is in contrast 
to the mechanism regulating agonist-dependent recycling for the β-2 adrenergic receptor  
(B2AR), where agonist washout actually increases recycling for B2AR (Vistein and 
Puthenveedu, 2013). It is unknown if receptor phosphorylation at serine 363 occurs at the 
plasma membrane or at the endosome. The timing and location of this phosphorylation may 
play a significant regulatory role in the receptor’s post-endocytic sorting and its ability to 
interact with downstream signaling complexes. This example again highlights the unique 
trafficking profiles of various GPCRs.  
 Moreover, previous work from the lab studied the role of serine 363 and threonine 370 in a 
heterologous PKC signaling model, which further emphasizes the importance of these 
phosphorylation sites on MOR with respect to receptor trafficking (Bowman et al., 2015). In 
chapter four, we explored how these sites contributed to endosomal signaling and ERK 
signaling. I did not observe statistically significant differences between phosphodeficient 
mutants S363A and T370A in endosomal recruitment of a biosensor that recognizes an active 
conformation of MOR. However, there may be differential coupling to G proteins and other 
signaling complexes in addition to differential sorting into endosomal compartments and 
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microdomains (Crilly et al., 2021; Bowman, 2016). Future studies should investigate how the 
spatial encoding of signals differs between relevant cell types.  
Overall my thesis work provides additional evidence for a hierarchical sorting model for 
GPCRs leading to spatially distinct signaling outcomes and increases our understanding of 
receptor physiology.  
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